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BACKGROUND: Studies show sedative-hypnotic medications (benzodiazepines 
[BZDs] and non-benzodiazepine receptor agonists [nBZRAs]) to be associated with 
adverse outcomes. This dissertation examined prescribing trends of these medications 
from 1993-2010, and comprised of three studies: study 1 examined trends in prescribing 
of sedative-hypnotics, study 2 examined physician practice style as a contributing factor 
for trends seen in study 1, and study 3 examined visits involving sedative-hypnotics in 
emergency departments (EDs).  
 
METHODS: Data for studies 1 and 2 came from the National Ambulatory Medical Care 
Survey (NAMCS). Study 1 analyzed trends in the proportion of visits from 1993-2010 
where a BZD and/or nBZRA was prescribed. Study 2 examined trends in the proportion 
of physicians prescribing BZDs and nBZRAs, as well as the predicted number of visits 
(based on regression models) that a BZD or nBZRA was prescribed among BZD and 
nBZRA prescribers respectively. Data for study 3 came from the Drug Abuse Warning 
Network. Analyses used logistic regression to determine the association between ED 
visits involving BZDs and/or nBZRAs and the seriousness of visit outcomes.  
 
RESULTS: From 1993-2010, we found increases in the proportion of visits resulting in a 
prescription for a BZD (from 2.6% to 4.4%, p<0.001) and a nBZRA (from 0% to 1.4%, 
p<0.001), as well as the co-prescribing of these agents at the same visit (from 0% to 0.4%, 
p<0.001). Over this same period, we observed increases in the proportion of NAMCS 
physicians each year who prescribed BZDs (from 23.8% to 44.4%, p<0.001) and 
 iii 
nBZRAs (from 1.0% to 25.8%, p<0.001), and in the predicted number of NAMCS visits 
that an nBZRA was prescribed among nBZRA prescribers (from 1.33 to 1.72, p<0.001). 
ED visits involving BZDs without nBZRAs and BZDs + nBZRAs were associated with 
increased odds for more serious outcomes compared to visits involving neither 
medication (odds ratio [OR]=1.34, 95% confidence interval [CI]=1.20-1.50 for BZDs 
without nBZRAs; OR=3.15, 95% CI=2.01-4.94 for BZDs + nBZRAs). 
 
CONCLUSIONS: Efforts to encourage safe prescribing of sedative-hypnotics, and 
greater dissemination of behavioral treatments for insomnia and anxiety disorders, could 
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Chapter 1: Introduction 
Overview of dissertation 
 Over the past two decades, a number of pharmacological agents have been 
developed to treat insomnia,1-3 a condition experienced by an estimated 50-70 million 
Americans.4 Benzodiazepines (BZDs) and non-benzodiazepine receptor agonists 
(nBZRAs), collectively known as sedative-hypnotic medications, induce sleep and lower 
anxious feelings by acting on the central nervous system.  BZDs, developed in the 1950s, 
are indicated for the treatment of anxiety disorders, insomnia, epilepsy, and alcohol 
withdrawal symptoms.5 In recent years, studies have shown that use of BZDs is 
associated with numerous adverse health outcomes in older adults, including falls6,7 and 
hip fractures,8,9 and decline in functional ability,10-12 prompting the development of 
clinical guidelines that strongly discourage the prescribing these medications to older 
people.13-17 
 The nBZRAs were introduced in the early 1990s,18-20 and were marketed as safer 
alternatives to BZDs for the short-term treatment of insomnia. Indeed—early clinical 
trials showed these agents to be safe and effective.21-24 However, recent observational 
studies have shown use of these medications may be associated with the same adverse 
health outcomes as seen for BZDs.25-27 
 Studies have shown that prescribing of BZDs remained relatively stable,28,29 and 
prescribing for nBZRAs increased,30 up to the early 2000s. There are also studies 
showing a rise in the number of emergency department (ED) visits involving BZDs and 
nBZRAs in recent years,31,32 suggesting that with the growing prescription of BZDs and 
nBZRAs, there has also been a rise in the occurrence of adverse health outcomes of these 
agents necessitating emergency treatment. While most research examining trends in 
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prescribing of BZDs and nBZRAs cover up until the early 2000s, little is known about 
recent trends in the prescribing of these agents. For example, we know little about how 
the introduction of nBZRAs in the early 1990s impacted overall prescribing of BZDs in 
later years, and whether these trends varied across patient groups (e.g., age, gender, and 
diagnoses of patients). In addition, more research is needed to examine the practice style 
of physicians who prescribe these medications, and to assess if changes in these styles 
over time may account for any changes seen in BZD and nBZRA prescribing overall.  
Finally, in light of studies showing BZDs and nBZRAs to be associated with adverse 
health outcomes,7,11,26,27,33 and the increasing trend in BZD- and nBZRA-related ED 
visits,31,32 more research is needed to understand the outcomes from these ED visits. 
 This dissertation examined how the prescribing and use of BZDs and nBZRAs 
changed between 1993 and 2010, and consists of three studies.  The first study examined 
trends in the prescribing of these medications from 1993-2010, and whether these trends 
varied among patients with different socio-demographic and clinical characteristics.  The 
second study sought to determine whether changes in prescribing of these medications 
was driven by changes in the number of physicians prescribing these medications, or the 
volume of prescriptions among BZD and nBZRA prescribing physicians, and whether 
these trends varied according to the age of the patients that the physician typically sees 
and the physician’s specialty.  Age of the patients is an important characteristic with 
regard to prescribing BZDs and nBZRAs because much of the clinical evidence regarding 
the harmful adverse effects of these medications has focused on older age patient groups. 
Finally, the third study examined the outcomes from a sample of emergency department 
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visits attributed to use of BZDs and nBZRAs, and assessed variations in these outcomes 
by age of patient at the visit. 
 The dissertation drew from data of two large nationally representative datasets: 
the National Ambulatory Medical Care Survey (NAMCS; studies 1 and 2) and the Drug 
Abuse Warning Network (DAWN; study 3).  NAMCS is a nationally representative 
annual cross-sectional study that examines the delivery of health services in ambulatory 
healthcare settings.  Physicians or their office staff were asked to report on a random 
sample of visits during a random one week interval. NAMCS provides data on diagnoses 
given, form of payment, and medications prescribed, among other variables.  DAWN is a 
public health surveillance system of visits to emergency departments where a substance 
was the cause of or a contributing factor to the visit. Substances are defined broadly and 
consist of both illicit substances and pharmacological agents used both medically and 
non-medically. Data include information on all the substances and medications involved, 
the reason for the visit, and the disposition after discharge from the emergency 
department.  Together, these large datasets provide unparalleled opportunities to assess 
trends in prescribing of BZDs and nBZRAs over the past two decades. 
The current chapter provides a background for the dissertation’s main studies. 
Specifically, it introduces the pharmacology of BZDs and nBZRAs, and reviews past 
research on prescribing trends of these agents. Finally, it describes efforts made to 
discourage the use and prescribing of these medications. 
 
Pharmacology of sedative-hypnotic medications 
Sedative-hypnotic medications elicit a calming physiological effect on the central 
nervous system. The first sedative-hypnotic that found common use was chloral hydrate, 
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a liquid bromide salt, that was first synthesized in 1832, and was eventually used 
clinically in the 1870s.5 With the subsequent development of barbiturates, and later BZDs, 
a number of medications were made available to induce a sense of calm. 
BZDs were first introduced in the 1950s in response to potential dangers in the 
use of barbiturates.5,34 BZDs are currently prescribed for a variety of conditions including 
anxiety, insomnia, muscle spasms, and seizure disorders.35 Barbiturates provided the 
same pharmacological effect as BZDs, but were considered to be dangerous because of 
the potential for dependence, withdrawal and toxicity.36 BZDs act on the central nervous 
system by enhancing the effect of the gamma-aminobutyric acid (GABA) 
neurotransmitter.35 GABA is an inhibitory neurotransmitter that suppresses central 
nervous system activity.1 BZDs bind to GABA receptors and magnify the effect of 
GABA, resulting in augmentation of GABA’s sedating and hypnotic effects. A list of the 
most commonly prescribed BZDs, their onset of action and elimination half-life is shown 
in Table 1.1, below. 
BZDs vary in their onset of action and elimination half-life. Onset of action is 
defined by the length of time it takes for the pharmacological agent to elicit the desired 
effect on the human nervous system.35 Elimination half-life is defined as the time it takes 
for the medication to lose half of its physiological effect.35 Availability of BZDs with 
different profiles of onset of action and elimination half-life is useful for clinicians when 
treating specific conditions. For example, to induce a prolonged sense of calm, a 
physician could prescribe a BZD with a long elimination half-life, in which the effect of 
the medication will continue to be present for one to three days after administration. To 
promote sleep, a physician can prescribe a BZD with a rapid onset of action and short 
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elimination half-life to help the patient fall asleep quickly, with little pharmacological 
effect when the patient awakes in the morning. For a patient who falls asleep easily but 
has difficulty remaining asleep, a BZD with a slow onset of action and moderately long 
elimination half-life may be preferable. 
 
Table 1.1: Benzodiazepines available in the US market 
Generic Brand Indications Onset (in 
hours) 
Elimination half-
life (in hours) 






















diazepam Valium Anxiety 
disorders 
1-1.5 48 
estazolam Prosom Insomnia 2 10-24 
flurazepam Dalmane Insomnia 0.5-1 47-100 
lorazepam Ativan Anxiety 
disorders 
2 12-18 
oxazepam Alepam Anxiety 
disorders 
3 5.7-10.9 
quazepam Doral Insomnia 2 39-73 
temazepam Restoril Insomnia 1.2-1.6 3.5-18.4 
triazolam Halcion Insomnia 2 1.5-5.5 
Note: Table aggregates data collected from the Drug Information Portal 
(http://druginfo.nlm.nih.gov/drugportal/) from the National Library of Medicine. All data is for the tablet or 
capsule version of the medication. 
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nBZRAs are medications that, similarly to BZDs, bind to GABA receptors to 
enhance the sedating and hypnotic effects of GABA neurotransmitters.  However, while 
BZDs non-selectively bind to all GABA receptors, the nBZRAs bind specifically to 
GABA-BZ receptors, and hence more selectively induce a sense of calm.24 The first 
nBZRA, zolpidem (brand name: Ambien), was introduced in December 1992.18 Since 
then, two other nBZRAs have been introduced: zaleplon (brand name: Sonata) introduced 
in August 1999,20 and eszopiclone (brand name: Lunesta) in December 2004.19 These 
agents were designed to have a significantly shorter onset of action and elimination half-
life than the BZDs.24 Their rapid onset of action makes them suitable for inducing sleep, 
and the fast elimination half-life make awaking in the morning easier.  Table 1.2 below 
provides a summary of the three medications in this class available in the US market.  
 
Table 1.2: Non-benzodiazepine receptor agonists available in the US market 
Generic Brand Indications Onset (in 
hours) 
Elimination half-
life (in hours) 
zolpidem Ambien Insomnia 1.6  2.6  
zaleplon Sonata Insomnia 1 1 
eszopiclone Lunesta Insomnia 1 6 
Note: Table aggregates data collected from the Drug Information Portal 
(http://druginfo.nlm.nih.gov/drugportal/) from the National Library of Medicine. All data is for the tablet or 
capsule version of the medication.  
 
Prescribing trends up until the early 2000s 
Prior to the 1970s, sedative-hypnotics were the drugs of choice for physicians 
treating psychiatric conditions.37,38 Prior to the 1950s, bromide salts and barbiturates were 
the primary sedative-hypnotics prescribed. In 1955, meprobamate (brand name: Miltown) 
was introduced as a mild sedative, and quickly became hugely popular—in 1957, nearly a 
third of prescriptions filled were for the medication.39 At the same time, BZDs were 
introduced and replaced use of meprobamate in the 1960s and 1970s when it was found 
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that meprobamate caused physical dependence.39 From the 1970s to the early 1990s, 
there was a substantial decrease in use of sedative-hypnotic prescriptions among the 
general population.37,40 Wysowski et al. found that the number of sedative-hypnotic 
prescriptions dispensed dropped from about 60 million in 1970 to roughly 30 million in 
1989.37 Interestingly, in this time there was a drastic drop in prescribing of barbiturates, 
and a marked increase in prescribing of BZDs, resulting in the majority of sedative-
hypnotics prescribed in 1989 being BZDs.37 
Studies show that prescribing of BZDs remained relatively unchanged through the 
1990s;28,29 however, there were large increases in prescribing of nBZRAs.  Moloney at al. 
found a nearly 30-fold increase in prescribing of nBZRAs from 1993-2007.30 Ford et al. 
also found that prescribing of nBZRAs increased nearly 300% from 1999-2010.41  There 
is also evidence showing increases in ED visits related to use of BZDs32 and nBZRAs31 
in recent years. One study found the number of ED visits involving zolpidem doubled 
from 2005-2010.31  
 
Concerns about BZD and nBZRA safety 
 Beginning in the 1970s, concerns grew about the safety profile of BZDs.  A 
number of studies showed an association between BZD use and falls6,7 and hip 
fractures.8,9,33 For example, Ray et al. found that use of long-acting BZDs was associated 
with an 80% increase in the odds of hip fractures compared to those not prescribed 
BZDs.33 Studies also show that use of BZDs is associated with functional impairment.10-
12 For example, Gray et al. found that older adults prescribed BZDs were over 20% more 
likely to develop mobility difficulties, and almost 30% more likely to develop 
impairment in activities of daily living (ADL) than those not taking these agents.11 
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Physiological studies have also shown that use of BZDs by older adults is associated with 
impaired balance,42,43 and lower physical strength and gait speed.44 
 Studies have also shown the use of nBZRAs to be associated with a number of the 
same adverse health outcomes as those from BZD use.27,45-48 For example, Wang et al. 
found that the use of zolpidem was associated with a doubling of the risk for hip fractures 
among older adults.27 Studies have also shown associations between the use of nBZRAs 
and functional impairment and impaired balance.26,49-51 Most recently, studies showed the 
use of these medications to be associated with severe next day drowsiness that impair 
driving abilities,52-55 increasing the risk of auto accidents.52,56 
 
Efforts to discourage BZD and nBZRA prescribing 
Due to safety concerns, there have been efforts to discourage the prescribing of 
these agents.  For example, clinical guidelines have provided recommendations on the 
safe prescribing of these and other potentially dangerous medications.13-15,17,57,58 The 
most commonly cited Beers Criteria15-17 list medications that could potentially lead to 
adverse health outcomes when used by older adults. The most recently updated version of 
the Beers Criteria includes both BZDs and nBZRAs.15 Physician organizations have also 
developed their own recommendations related to BZD and nBZRA use.59,60 For example, 
the American Psychiatric Association in its guidelines for the treatment of panic disorder 
suggests that BZDs be used only as a short-term treatment.59 The American Academy of 
Sleep Medicine guidelines for the treatment of insomnia recommend medications to be 
used only if behavioral treatments do not provide symptomatic relief.60 
Monitoring programs have also sought to provide barriers to inappropriate 
prescribing of these medications. For example, New York state implemented a triplicate 
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prescribing program for BZDs which resulted in a decline of BZD prescribing by nearly 
half.61 Some studies have assessed the efficaciousness of educational visits with 
prescribers that include discussions on safe prescribing of BZDs and nBZRAs.62,63 
Electronic medical records have also integrated reminders about potential dangers when 
prescribing BZDs and nBZRAs to patients at risk for adverse outcomes.64 
Finally, there have been federal legislative efforts to discourage unsafe 
prescribing of these medications.  With the implementation of Medicare Part D in 2006, 
BZDs were excluded from reimbursement.65 The Food and Drug Administration has also 
lowered the recommended dose for prescribing of zolpidem, and later zaleplon and 
eszopiclone, to women.66,67 
 
Unanswered questions 
 In light of research showing adverse health outcomes associated with the use of 
BZDs and nBZRAs, and the many efforts to discourage their use, more research is 
needed to understand trends in the use of these agents. We know little about the impact of 
the introduction of nBZRAs on prescribing of BZDs, and how these trends differed by 
different patient groups and different visit types.  Further, we know little about the extent 
to which any change in prescribing of BZDs and nBZRAs is driven by the number of 
physicians prescribing these medications or the volume in prescribing per physician. 
Finally, in light of increased ED visits related to BZD and nBZRA use,68,69 more research 
is needed to assess the outcomes of these visits. This dissertation addressed these 
questions to enhance understanding of sedative-hypnotic prescribing in recent years. The 
findings have potential implications for future policy initiatives aimed at curbing the un-
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necessary use of these medications and reducing the adverse outcomes associated with 
their use.  
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Chapter 2: Trends in prescribing of benzodiazepines and non-





BACKGROUND: Non-benzodiazepine receptor agonists (nBZRAs) were developed as 
an alternative to benzodiazepines (BZDs) for the treatment of insomnia.  However, little 
is known about how their introduction influenced trends in the use of BZDs. The purpose 
of this study was to describe trends in the prescribing of BZDs and nBZRAs between 
1993 and 2010. 
 
METHODS: Data came from the National Ambulatory Medical Care Survey, which 
consists of physician-reported information on patient visits. Our study included a total of 
516,118 patient visits between 1993 and 2010. We categorized these visits as BZD, 
nBZRA, and BZD + nBZRA visits based on the medications prescribed during each visit. 
Linear probability regression models were used to assess trends in the proportion of all 
visits for the three visit types over the study period. 
 
RESULTS: Between 1993 and 2010, there were increases in the proportion of visits that 
were BZD (from 2.6% in 1993 to 4.4% in 2010, p<0.001) and nBZRA visits (from 0% to 
1.4%, p<0.001). We also found an increase in visits in which both BZDs + nBZRAs were 
prescribed (from 0% to 0.4%, p<0.001).  While there was a large statistically significant 
increase in nBZRA visits for patients with a sleep disorder (B=0.099, 95% CI=0.045-
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0.153), there was also a statistically significant decline in BZD visits for the same type of 
visit (B=-0.071, 95% CI=-0.128- -0.014). 
 
CONCLUSION: The introduction of nBZRAs as a safer sedative-hypnotic option for 
treating insomnia likely resulted in declines in prescribing of BZDs for treatment of sleep 
disorders, but not among other groups of patients.  Efforts should be made to encourage 
the delivery of behavioral treatments for anxiety disorders and insomnia to patients 





As of 2013, it is estimated that 9 million adults in the United States use 
prescription medication to help them sleep.70 The most common medications used to treat 
sleep disorders include benzodiazepines (BZDs) and non-benzodiazepine receptor 
agonists (nBZRAs).2 Both are sedative-hypnotics that act on the GABA-A 
neurotransmitter receptor to induce a sedative effect and to promote sleep.2  BZDs, the 
older of the two classes, were discovered in the early 1950s, and are approved by the 
Food and Drug Administration (FDA) for treatment of a broad range of disorders 
including anxiety and seizure disorders, as well as insomnia.5  nBZRAs were introduced 
in the early 1990s, and are approved by the FDA for the short-term treatment of 
insomnia.18-20 
The development of nBZRAs was prompted by concerns about the safety and 
tolerability of BZDs—which were shown to be associated with a number of unwanted 
side effects among older adults, including falls,6,7 hip fractures,8,9 cognitive impairment,71 
and disability.10-12 Approved by the FDA in December 1992, zolpidem (marketed as 
Ambien) was the first nBZRA that entered the US market.18 Since then, a number of 
other nBZRAs have been introduced, including zaleplon (brand name: Sonata, approved 
August 1999)20 and eszopliclone (brand name: Lunesta, approved December 2004).19 
These nBZRAs were marketed as safer alternatives to the BZDs.21,22,24 
Little is known about any possible changes in prescription of BZDs after the 
introduction of nBZRAs. Prior to the introduction of nBZRAs in the mid-1990s, BZDs 
were among the most common sedative-hypnotic medications prescribed.72 Since their 
introduction in the 1950s, prescribing of this class of medications has increased 
 14 
exponentially.37 Wysowski et al. found that prescriptions dispensed for BZDs increased 
from 0.7 million prescriptions in 1970 to 17.9 million in 1989.37 BZDs have been found 
to be most commonly used by women73 and older adults.74 
The extent to which BZDs and nBZRAs are prescribed together has not been 
examined. Co-administration of these medications could be dangerous due to the 
potential for adverse drug interactions.75 The co-use of BZDs and nBZRAs is especially 
of concern in light of emerging evidence showing that nBZRAs may be associated with 
the same harmful side effects as BZDs.  There have been a number of high profile cases 
of car accidents associated with the use of these medications in the popular media,76,77 
and some research indicates an association between use of nBZRAs and falls,25,26 and hip 
fractures.27 As a result, the FDA lowered the recommended doses for zolpidem in 2013, 
and for zaleplon and eszopliclone in 2014.67 
The aim of this study was to describe national prescribing trends of both BZDs 
and NBZRAs from 1993-2010.  We examined trends in the prescribing of these 
medications by patient and visit characteristics. We hypothesized that overall, there was 
an increase in prescribing of nBZRAs during the study period, coinciding with a decline 




 Data for this study came from the 1993-2010 waves of the National Ambulatory 
Medical Care Survey (NAMCS).78  NAMCS is an annual cross-sectional survey 
conducted by the National Center for Health Statistics (NCHS), which examines the use 
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and delivery of health services in ambulatory healthcare settings in the United States.79 
Each year, a nationally representative sample of physicians is asked to report on a 
random selection of patient visits in a random week. Physicians are sampled using a 
multistage probability sampling design based on the American Medical Association 
Master File.  From 1993-2010, the number of visits each year included in our analysis 
ranged from 20,760 to 36,875, resulting in a total study sample of 516,118 patient visits.  
Over the past 20 years, the response rates for NAMCS have ranged from 60-70%. 
 
Measures 
Prescription medications. For each visit, NAMCS lists all prescriptions and over-
the-counter drugs that were “ordered, supplied, administered or continued” at a given 
patient visit. For the NAMCS 1993-2002 waves, up to 6 medications were recorded for 
each visit. Starting in 2003, the maximum number of medications recorded was increased 
to 8. To make the years comparable, we limited the maximum number of medications to 
6 in all years (i.e., we only considered the first 6 medications listed). For the purposes of 
this study, nBZRAs were defined as zolpidem, zaleplon, and eszopiclone; BZDs were 
defined as alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, 
flurazepam, lorazepam, oxazepam, temazepam, and triazolam.  We categorized each visit 
into one of the following four mutually exclusive groups: “no BZD nor nBZRA visits”, 
“BZD visits,” “nBZRA visits,” and “BZD + nBZRA visits”. In this paper we refer to the 
last three groups as “any sedative-hypnotic visits.” Of note, other medications besides 
BZD and nBZRAs could have been prescribed at any of the visits. Other sedative-
hypnotic medications were not examined in this study. 
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Patient characteristics.  NAMCS recorded patients’ demographic characteristics, 
including age (which we categorized as <25, 25-44, 45-64, and 65+ years), gender 
(female, male), and race/ethnicity (categorized as non-Hispanic white, non-Hispanic 
black, Hispanic, and other). NAMCS also recorded diagnoses related to the visit 
including the presence of “chronic conditions,” identifying one “primary diagnosis,” as 
well as two “other” diagnoses if applicable. NCHS staff coded diagnoses listed based on 
ICD-9 codes. Based on these three listed diagnoses, we identified patients as having 
either a sleep, anxiety, or mood disorder based on ICD-9 codes (sleep disorders: 307.40-
307.49, 327.00-327.8, 780.50-780.59; anxiety disorders: 300.00-300.9; mood disorders: 
296.00-296.99). 
Visit characteristics. NAMCS also recorded whether the visit was by a new 
patient or an established patient, and whether a follow-up appointment was scheduled at 
the time of visit. The expected source(s) of payment for the visit was also recorded, 
which we categorized into private insurance, Medicare, Medicaid, self-pay, or other 
(including worker compensation, no pay, other, and unknown). Physician’s specialty was 
ascertained from the American Medical Association Master File, and was confirmed with 
physicians when they were enrolled in the study.  We categorized physicians as primary 
care physicians (including general/family practice and internal medicine), psychiatrists, 
and other (e.g., pediatrics, general surgery, urology, etc.).  
 
Analyses 
Analyses were conducted in three stages.  First, we compared the characteristics 
of any sedative-hypnotic visit to visits where no sedative-hypnotic was prescribed using 
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bivariate logistic regression.  The dependent variable in these analyses was the visit type 
(e.g., any sedative-hypnotic visit vs. no sedative-hypnotic visit), and the independent 
variables were the characteristics of the visit.  To ascertain differences among the various 
types of sedative-hypnotic visits (i.e., BZD, nBZRA, and BZD + nBZRA visits), we 
compared both nBZRA visits and BZD + nBZRA visits to BZD visits using multinomial 
logistic regression.  For example, the characteristics of nBZRA visits were compared to 
the characteristics of BZD visits, and the characteristics of BZD + nBZRA visits were 
also compared to the characteristics of BZD visits. These latter analyses were limited to 
any sedative-hypnotic visits.   
Second, we examined trends in the prevalence of different visit types across time 
(BZD visits, nBZRA visits, and BZD + nBZRA visits) using logistic regression models.  
As suggested by the NCHS,80 we binned years into 2-year windows in order to improve 
the reliability of our estimates, and assigned a number ranging from 1-9 based on these 
binned groups (e.g., 1 = “1993-1994,” 2 = “1995-1996,” etc.).  Consistent with prior 
studies using the NAMCS,81 this time indicator variable was then transformed by 
subtracting 1 and dividing by 8 (the range of values for the time variable).  Thus, this 
transformed variable ranged from 0 to 1 and the resulting coefficients computed from the 
regression models represent changes in the odds of each type of visit over the entire study 
period (e.g., 1993-2010). 
Because the prevalence of nBZRA prescriptions in the 1993-1994 period was 
very low, the logistic regression models produced very large odds ratios for the trends in 
prescriptions of these medications, limiting our ability to compare trends across 
medication classes. To represent trends in prescribing that were more comparable across 
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medication classes, we estimated the absolute change in prescription of these medications 
over time using linear probability regression models.82 The outcome for these analyses 
was the dichotomous variable for the prescription of each medication type. The 
regression coefficients in the linear probability models represent change in prevalence of 
prescriptions for each medication type. Because results of statistical tests for the logistic 
regressions and linear probability models were quite similar, here we report results from 
linear probability models only. 
 The analyses were repeated after stratifying the sample based on patient and visit 
characteristics.  Specifically, we stratified results by patient age, gender, race/ethnicity, 
new- or established-patient status, whether a follow-up was scheduled, main payment 
source, physician specialty, and diagnoses of sleep, anxiety and mood disorders.  Finally, 
we statistically tested whether the trends in prescribing differed across strata by testing 
interaction terms of time with indicator variables identifying each stratum compared to all 
other strata. A statistically significant interaction term suggests that trends differ across 
strata. These tests adjusted for all patient and visit characteristics examined in our study. 
 
RESULTS 
Prevalence and characteristics of BZD and nBZRA visits 
Among all patient visits from 1993-2010, there were 17,972 (3.5%, unweighted) 
BZD visits, 3,042 (0.6%, unweighted) nBZRA visits, and 884 (0.2%, unweighted) BZD + 
nBZRA visits.  Among any visit for which a sedative hypnotic was prescribed (n=21,898), 
the majority were for patients aged 45 years or older (45-64 years old: 40.5%; 65+ years 
old: 30.8%), two-thirds involved women, and over four-fifths involved non-Hispanic 
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white patients (Table 1.1).  Over one-fifth of all sedative-hypnotic visits were for patients 
diagnosed with an anxiety disorder, 11.0% for patients with a mood disorder, and 5.3% 
for those with a sleep disorder. The majority of any sedative-hypnotic visits were for new 
patients (92.8%) and involved scheduling a follow-up visit (96.6%).  The most common 
payment sources for these visits were private insurance (48.0%), and Medicare (32.1%).  
Over half of the visits were with primary care doctors, and 19.1% were with psychiatrists. 
Compared to visits where no sedative-hypnotic was prescribed, visits where any sedative-
hypnotic was prescribed were more likely to be for patients who were older than age 45 
(71.3% vs. 51.4%), female (66.6% vs. 58.9%), non-Hispanic white (83.5% vs. 76.2%), 
diagnosed with a sleep (5.3% vs. 0.6%), anxiety (20.3% vs. 1.3%), or mood disorder 
(11% vs. 1.0%), to involve new patients (92.8% vs. 86.7%), to include scheduling of a 
follow-up appointment (96.6% vs. 92.3%), to be paid for by Medicare (32.1% vs. 22.5%) 
or to be self-pay (7.1% vs. 4.8%), and to involve a primary care physician (53.2% vs. 
38.4%) or psychiatrist (19.1% vs. 2.3%). Compared to visits where no sedative-hypnotic 
was prescribed, visits where any sedative-hypnotics were prescribed were less likely to 
involve physicians with other specialty (27.7% vs. 59.3%) (all p’s<0.001) (Table 2.1).  
Compared to BZD visits, nBZRA visits were more likely to be for patients older 
than age 45 (77.7% vs. 70.2%), male (35.7% vs. 33.1%), of Hispanic ethnicity (8.6% vs. 
7.0%) or other race (3.5% vs. 2.1%), and to be diagnosed with a sleep disorder (15.3% vs. 
3.1%), and were less likely to be for patients diagnosed with an anxiety (6.1% vs. 22.6%) 
or mood disorder (7.6% vs. 11.2%), reimbursed by Medicare (31.3% vs. 32.7%), 
Medicaid (7.1% vs. 9.4%), to be self pay (4.3% vs. 7.7%), or reimbursed by another 
payment source (2.9% vs. 4.0%), and to involve a psychiatrist (11.2% vs. 19.9%) (all p’s 
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<0.05) (Table 2.2). Compared to BZD visits, BZD + nBZRA visits were more likely to be 
with patients between age 25-64 (77.7% vs. 64.9%), diagnosed with a sleep (8.3% vs. 
3.1%), anxiety (31.0% vs. 22.6%), or a mood disorder (22.0% vs. 11.2%), and to involve 
a psychiatrist (35.5% vs. 19.9%), and less likely to be reimbursed by Medicare (23.9% vs. 
32.7%) (all p’s<0.008). 
 
Temporal trends in prescriptions 
The percentage of visits involving BZDs rose from 2.6% in 1993 to 4.4% in 2010 
(B = 0.019, 95% Confidence Interval [CI] = 0.015-0.024, p<0.001) (Figure 2.1).  
Similarly, the percentage of visits involving nBZRAs increased from 0% in 1993 to 1.4% 
in 2010 (B = 0.015, 95% CI=0.013-0.016, p<0.001).  The percentage of visits involving 
BZDs + nBZRAs increased from 0% in 1993 to 0.3% in 2010 (B = 0.004, 95% 
CI=0.003-0.004, p<0.001). 
There were statistically significant increases in BZD visits across most patient and 
visit characteristics in stratified analyses (Table 2.3).  However, there was a statistically 
significant decrease in BZD visits for patients diagnosed with a sleep disorder (B = -
0.071, 95% CI=-0.128- -0.014), and no statistically significant change in BZD visits 
among patients from the heterogeneous “other” race/ethnicity, visits to psychiatrists, or in 
visits by patients diagnosed with an anxiety or mood disorder.  There were significant 
interactions with the time variable for age, gender, race/ethnicity, and new patient status. 
The trend was less pronounced for visits by patients <25 years old compared to other age 
groups (F[1, 4624] = 28.45; p<0.001). In contrast, the trend was more pronounced in 
visits by patients in the 45-64 years age range compared to other age groups (F[1, 4624] 
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= 13.46; p<0.001), for females compared to males (F[1, 4624] = 6.56; p=0.011), non-
Hispanic blacks compared to all other race/ethnicities (F[1, 4624] = 7.99; p=0.005), and 
for new patients compared to established patients (F(1, 4624) = 4.45; p=0.035). 
 There were increases in nBZRA visits across all patient and visit characteristics, 
with particularly large increases among visits with patients diagnosed with sleep 
disorders (B=0.099, 95% CI=0.045-0.153). There were significant interactions with the 
time variable for age, race/ethnicity, main payment source, physician specialty, and mood 
disorders. The trend was less pronounced for visits with patients <25 years old compared 
to other age groups (F[1, 4624] = 107.16; p<0.001), Medicaid reimbursement compared 
to other forms of reimbursement (F[1, 4624] = 5.55; p=0.019), and other physician 
specialty compared to primary care physicians and psychiatrists combined (F[1, 4624] = 
28.24; p<0.001).  The trend was more pronounced for visits with patients aged 45-64 
compared to other age groups (F[1, 4624] = 20.88; p<0.001), for non-Hispanic whites 
compared to other race and ethnicities (F[1, 4624] = 6.67; p=0.010), for physicians with a 
primary care (F[1, 4624] = 17.81; p<0.001) and  psychiatry specialty (F[1, 4624] = 7.20; 
p=0.007) compared to other specialties and for visits of patients with a mood disorder 
compared to all other visits (F[1, 4624] = 9.38; p=0.002).  
Finally, there were increases in BZD + nBZRA visits by all patient and visit 
characteristics, except for visits with patients aged <25 years, with unscheduled follow-
ups and those reimbursed by Medicaid.  Significant interactions with time were found for 
age, gender, race, follow-up, main payment source, physician specialty, and all diagnoses. 
Trends were significantly less pronounced for visits with patients <25 years compared to 
all other age groups (F[1, 4624] = 42.30; p<0.001), for males compared to females (F[1, 
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4624] = 4.13; p=0.042), for the “other” racial group compared to all Hispanic and non-
Hispanic whites and blacks (F[1, 4624] = 3.93; p=0.047), for visits reimbursed by 
Medicaid (F[1, 4624] = 4.35; p=0.037), and for other physician specialty versus 
psychiatry and primary care specialties combined (F[1, 4624] = 21.51; p<0.001). The 
trend was more pronounced for visits with patients aged 45-64 compared to all other age 
groups (F[1, 4624] = 5.38; p=0.020), for non-Hispanic whites compared to all other 
racial/ethnic groups (F[1, 4624] = 7.74; p=0.005), for visits with a scheduled compared to 
unscheduled follow-up (F[1, 4624] = 5.18; p=0.023), for visits with psychiatrists 
compared to all other physician specialties (F[1, 4624] = 20.82; p<0.001), for visits by 
patients with an anxiety disorder (F[1, 4624] = 19.46; p<0.001) or mood disorder 
diagnoses (F[1, 4624] = 13.79; p<0.001) compared to visits without those diagnoses. 
 
DISCUSSION 
 This study examined trends in prescription of BZD and nBZRA agents overall 
and in different patient groups between 1993 and 2010. We found that during the study 
period, prescribing of nBZRAs as well as BZDs each rose, with increases seen in 
different patient group and visit types.  We also found a substantial decline in prescribing 
of BZDs among patients with sleep disorders, coinciding with a dramatic increase in 
prescription of nBZRAs in visits involving these patients. This finding suggests that 
nBZRAs may have partly replaced BZDs in treatment of sleep disorders in this period. 
Nevertheless, the introduction of nBZRAs does not appear to have impacted the 
overall BZD prescribing trend over our study period—rather, we observed a large 
increase in prescribing of BZDs after 2002.  Although nBZRAs are only indicated for 
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short-term treatment of insomnia and thus unlikely to influence prescription of BZDs for 
other indications, the growing concerns about adverse health outcomes associated with 
the use of these medications6-12,71 and the expanding indications of selective serotonin 
reuptake inhibitors for treatment of anxiety in addition to mood disorders59,83 in this 
period do not appear to have reduced BZD prescriptions. This finding is surprising in 
light of prior studies in the US and other countries showing either no change or a decline 
in prescriptions for BZDs between the 1990s and early 2000s.28,84,85 From our analyses, it 
appears that from 2002-2010, increases in prescribing of BZDs were particularly 
pronounced in visits to primary care doctors. This change in prescription patterns for 
BZDs in the primary care settings is in line with increased prescribing of other 
psychiatric medications in this setting and may indicate greater recognition or diagnosis 
of mental health problems.86 Better understanding of these physicians’ prescribing 
practices would help inform initiatives to improve the prescription of BZDs in this setting.    
We also found that an increasing trend of co-prescribing of the two medication 
classes, with the strongest trend seen among visits to psychiatrists as well as those 
involving patients diagnosed with sleep, anxiety and/or mood disorders. The finding of 
increases in co-prescribing of BZDs and nBZRAs during the same visit is disconcerting, 
but is consistent with research indicating growing polypharmacy in outpatient 
psychiatry.81 The risks associated with the use of BZDs are well established.6-12,71 
Evidence regarding the hazards of nBZRAs has also been growing.25-27,67 The use of both 
BZDs and nBZRAs together in healthier populations has been shown to modestly 
increase the medications’ sedative properties,87 but there has been a dearth of studies 
examining drug-drug interactions in vulnerable population groups such as older adults. 
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Given that BZDs and nBZRAs act on the same GABA receptors, use of the two 
medication classes could potentially increase the hazards associated with the use of each.  
It is plausible that prescriptions for these medications were for different indications (e.g., 
BZDs for anxiety disorders and nBZRAs for insomnia), which would not be surprising 
given that anxiety disorders, like many other psychiatric conditions, are often associated 
with sleep problems.2 However, given the risk associated with the use of these 
medications individually, and the lack of information about their possible interaction 
effects, combining them should be done with caution, especially in vulnerable 
populations.  
 Our study also found that prescription of BZDs and nBZRAs was very common 
among older patients, occurring in just under a third of visits for those aged 65+ years.  
This finding supports results from previous studies, which show a high prevalence of use 
of sedative-hypnotics among older adults.88-92 Our study adds to this literature by 
showing that this pattern was consistent across BZD, nBZRA, and BZD + nBZRA visits.  
 In our study, visits reimbursed by Medicaid were less likely to result in 
prescriptions for nBZRAs, but there was no difference in terms of Medicaid 
reimbursement for BZD visits.  This finding may reflect Medicaid formulary limitations 
or requirements for pre-authorization in some states. While little is known about the 
relative safety of nBZRAs, it is of concern that disadvantaged patients may not be 
receiving medications that may prove to be safer. 
 As nBZRAs gradually lose their patents, newer sleep-aids have been introduced 
into the market.93 For example, zolpidem tartrate (brand name: Intermezzo) was 
introduced in November 2011, and is approved for treatment of middle of the night 
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awakenings.94 Similarly, a new medication to help with regulating circadian rhythm 
abnormalities in blind patients (tasimelteon, brand name: Hetlioz) was approved by the 
FDA in January 2014.95 The most recently approved insomnia medication, suvorexant 
(brand name: Belsomra) acts by blocking orexin (which promotes wakefulness).96 
Because patients in clinical trials submitted to the FDA are often healthier and younger 
than typical users of these medications in the real world, it will be important to fully 
examine the health consequences of these newer sedative-hypnotics in broader population 
samples. 
 Over the years, a number of non-pharmacological treatments for anxiety and 
insomnia have been developed.97,98 Among these, cognitive behavioral therapy has 
proven effective in minimizing anxiety and improving overall quality of life.99 Cognitive 
behavior therapy for insomnia has been shown to be more effective than the use of 
sedative-hypnotics in treating insomnia in the long term.100 Greater efforts should be 
made to replace sedative-hypnotic prescribing with these non-pharmacological treatments 
in usual treatment settings. 
This study had a number of limitations.  First, data for the NAMCS are based on a 
single office visit. Many individuals, especially those with comorbid conditions, see 
multiple providers. Our estimates of BZD and nBZRA use may thus be conservative, and 
sedative-hypnotic prescribing may be even more prevalent than our study suggests. 
Second, all data on patient visits were reported by physicians or their office staff using 
medical records.  Therefore, the data are prone to reporting and recording errors. It is also 
possible that data from busier offices with more patients may be less detailed or have 
more missing data than smaller office settings.  Finally, NAMCS limits the number of 
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medications reported to six, but many individuals, especially older adults, are known to 
use a greater number of medications.101 
 In the context of these limitations, findings from this study provide a description 
of temporal trends in prescription of BZDs and nBZRAs over the past two decades. 
Prescriptions for these medications have been increasing despite concerns about their 
safety.  While the introduction of nBZRAs may have led to fewer prescriptions for BZDs 
to those with sleep disorders, prescribing of BZDs to other patient groups still increased 
during the study period.  Furthermore, the study recorded a concerning trend of co-
prescription of these medication groups. As safer behavioral treatment alternatives are 
often available for many of the target conditions of these medications, efforts should be 




Figure 2.1: Trends in prescribing of benzodiazepine and non-benzodiazepine receptor 






Table 2.1: Patient and visit characteristics of ambulatory healthcare office visits in which 
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OR (95% CI) 
Age    
<25 years 113,595 (25.8) 1,011 (3.6) Ref. 
25-44 114,405 (22.7) 5,864 (25.1) 7.83 (7.05, 8.69) 
45-64 135,242 (26.4) 8,872 (40.5) 10.89 (9.81, 12.09) 
65+ 130,978 (25.0) 6,151 (30.8) 8.73 (7.83, 9.73) 
Gender    
Female 282,846 (58.9) 14,331 (66.6) Ref. 
Male 211,374 (41.1) 7,567 (33.4) 0.72 (0.69, 0.75) 
Race    
Non-Hispanic White 382,100 (76.2) 18,430 (83.5) Ref. 
Non-Hispanic Black 45,667 (9.6) 1,418 (7.0) 0.66 (0.60, 0.73) 
Hispanic 46,417 (10.0) 1,495 (7.3) 0.66 (0.59, 0.74) 
Other 20,036 (4.2) 555 (2.3) 0.50 (0.42, 0.58) 
Diagnosis    
Sleep 3,150 (0.6) 923 (5.3) 9.21 (8.09, 10.48) 
Anxiety 8,540 (1.3) 4,773 (20.3) 19.05 (17.69, 20.51) 
Mood 8,270 (1.0) 3,525 (11.0) 11.82 (10.86, 12.88) 
Patient status    
New 412,100 (86.7) 19,851 (92.8) Ref. 
Established 79,959 (13.3) 1,994 (7.3) 0.51 (0.47, 0.55) 
Follow-upd    
Scheduled 361,704 (92.3) 15,868 (96.6) Ref. 
Unscheduled 26,563 (7.7) 419 (3.4) 0.42 (0.36, 0.50) 
Main payment sourcee    
Private insurance 188,546 (57.3) 7,950 (48.0) Ref. 
Medicare 83,253 (22.5) 5,170 (32.1) 1.70 (1.59, 1.81) 
Medicaid 38,348 (10.5) 1,811 (9.0) 1.03 (0.92, 1.15) 
Self-pay 19,834 (4.8) 1,651 (7.1) 1.77 (1.57, 1.99) 
Otherf 18,489 (4.9) 760 (3.8) 0.92 (0.79, 1.06) 
Physician specialty    
Other specialty 347,896 (59.3) 7,955 (27.7) Ref. 
Primary care 125,835 (38.4) 7,152 (53.2) 2.97 (2.73, 3.24) 
Psychiatry 20,489 (2.3) 6,791 (19.1) 18.01 (16.18, 20.04) 
Note: All analyses account for the complex sampling design of the NAMCS, and are nationally representative. 
a Benzodiazepines include: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, 
oxazepam, temazepam, and triazolam. 
b Non-benzodiazepine receptor agonists include: zolpidem, zaleplon, and eszopliclone.   
c All percentages are weighted to make results nationally representative. 
d This item was not assessed in 1997-1998, and 2009-2010. 
e This item was not assessed in 1993-1996. 
f Other payment source included worker compensation, no pay, other, and unknown. 
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Table 2.2: Comparison of patient and visit characteristics of ambulatory healthcare office 
visits involving benzodiazepines (BZD), non-benzodiazepine receptor agonists (nBZRA), 




























BZD + nBZRA 
vs. BZD visits 
 
OR (95% CI) 
      
Age      
<25 years 889 (4.0) 108 (2.4) Ref. 14 (1.6) Ref. 
25-44 4,923 (25.9) 672 (20.0) 1.31 (0.96, 1.79) 269 (29.4) 2.87 (1.33, 6.19) 
45-64 7,072 (39.0) 1,363 (46.5) 2.03 (1.50, 2.75) 437 (48.3) 3.14 (1.47, 6.71) 
65+ 5,088 (31.2) 899 (31.2) 1.71 (1.24, 2.35) 164 (20.7) 1.68 (0.76, 3.70) 
Gender      
Female 11,783 (66.9) 1,931 (64.3) Ref. 617 (69.1) Ref. 
Male 6,189 (33.1) 1,111 (35.7) 1.12 (1.00, 1.26) 267 (30.9) 0.90 (0.71, 1.15) 
Race      
Non-Hispanic White 15,202 (84.1) 2,471 (80.6) Ref. 757 (83.1) Ref. 
Non-Hispanic Black 1,148 (6.9) 215 (7.3) 1.11 (0.91, 1.34) 55 (6.9) 1.01 (0.68, 1.52) 
Hispanic 1,190 (7.0) 248 (8.6) 1.28 (1.03, 1.61) 57 (8.0) 1.15 (0.76, 1.75) 
Other 432 (2.1) 108 (3.5) 1.77 (1.24, 2.52) 15 (2.1) 1.01 (0.51, 1.98) 
Diagnosis      
Sleep 455 (3.1) 408 (15.3) 5.62 (4.66, 6.79) 60 (8.3) 2.83 (1.87, 4.29) 
Anxiety 4,263 (22.6) 248 (6.1) 0.22 (0.19, 0.26) 262 (31.0) 1.54 (1.24, 1.91) 
Mood 2,877 (11.2) 388 (7.6) 0.65 (0.55, 0.78) 260 (22.0) 2.24 (1.80, 2.80) 
Patient status      
New 16,283 (92.8) 2,750 (92.2) Ref. 818 (93.2) Ref. 
Established 1,638 (7.2) 290 (7.8) 1.09 (0.90, 1.32) 66 (6.8) 0.94 (0.66, 1.35) 
Follow-upd      
Scheduled 13,251 (96.5) 2,024 (97.1) Ref. 593 (96.6) Ref. 
Unscheduled 355 (3.5) 55 (2.9) 0.83 (0.57, 1.21) 9 (3.4) 0.99 (0.45, 2.15) 
Main payment sourcee      
Private insurance 6,083 (46.2) 1,440 (54.5) Ref. 427 (53.6) Ref. 
Medicare 4,148 (32.7) 842 (31.3) 0.81 (0.70, 0.94) 180 (23.9) 0.63 (0.48, 0.83) 
Medicaid 1,480 (9.4) 231 (7.1) 0.64 (0.50, 0.82) 100 (11.6) 1.07 (0.74, 1.54) 
Self-pay 1,373 (7.7) 192 (4.3) 0.47 (0.37, 0.60) 86 (7.6) 0.85 (0.57, 1.25) 
Otherf 621 (4.0) 104 (2.9) 0.60 (0.41, 0.88) 35 (3.3) 0.71 (0.44, 1.14) 
Physician specialty      
Other specialty 6,519 (27.3) 1,220 (31.3) Ref. 216 (20.3) Ref. 
Primary care 5,756 (52.8) 1,168 (57.5) 0.95 (0.80, 1.12) 228 (44.3) 1.13 (0.87, 1.46) 
Psychiatry 5,697 (19.9) 654 (11.2) 0.49 (0.40, 0.60) 440 (35.5) 2.41 (1.82, 3.17) 
Note: All analyses account for the complex sampling design of the NAMCS, and are nationally representative. 
a Benzodiazepines include: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, 
oxazepam, temazepam, and triazolam. 
b Non-benzodiazepine receptor agonists include: zolpidem, zaleplon, and eszopliclone.   
c All percentages are weighted to make results nationally representative. 
d This item was not assessed in 1997-1998, and 2009-2010. 
e This item was not assessed in 1993-1996. 




Table 2.3: Stratified analyses for temporal trends in prescribing of benzodiazepine and non-benzodiazepine receptor agonists during 
ambulatory medical office visits, National Ambulatory Medical Care Survey 1993-2010 
 Yearsa Trendb Interaction with Timec 
 
 













































F-statistic (df), p-value 
BZD visits            
Age            
<25 years 0.26 0.32 0.29 0.65 0.46 0.66 0.63 0.62 0.76 0.005 (0.003, 0.006) F(1, 4624) = 28.45; <0.001 
25-44 2.74 3.03 2.70 3.08 3.33 3.86 4.06 5.06 5.42 0.027 (0.021, 0.034) F(1, 4624) = 0.94; 0.332 
45-64 3.79 4.15 3.96 4.13 3.78 4.00 5.30 6.19 5.93 0.025 (0.017, 0.034) F(1, 4624) = 13.46; <0.001 
65+ 3.60 3.57 4.17 3.82 3.44 2.97 4.41 4.93 4.95 0.013 (0.006, 0.021) F(1, 4624) = 0.06; 0.807 
Gender            
Female 2.80 2.99 3.12 3.18 3.17 3.35 4.16 4.91 4.92 0.023 (0.017, 0.029) F(1, 4624) = 6.56; 0.011 Male 2.08 2.24 2.16 2.61 2.17 2.27 2.95 3.38 3.56 0.015 (0.010, 0.019) 
Race            
Non-Hispanic White 2.64 2.73 3.14 3.26 3.01 3.22 4.12 4.84 4.90 0.024 (0.018, 0.029) F(1, 4624) = 1.61; 0.204 
Non-Hispanic Black 2.16 2.51 1.39 1.97 2.20 2.29 1.72 2.64 3.87 0.014 (0.007, 0.021) F(1, 4624) = 7.99; 0.005 
Hispanic 2.01 2.78 1.28 1.76 1.35 2.01 3.12 3.12 2.25 0.009 (0.000, 0.018) F(1, 4624) = 0.72; 0.398 
Other 1.38 1.84 1.08 1.55 1.58 1.02 1.31 2.64 1.89 0.007 (-0.002, 0.017) F(1, 4624) = 1.24; 0.265 
Patient status            
New 2.72 2.86 3.00 3.13 2.98 3.10 3.86 4.57 4.65 0.020 (0.015, 0.025) F(1, 4624) = 4.45; 0.035 Established 1.41 1.63 1.17 1.87 1.17 1.38 2.23 2.40 2.52 0.012 (0.006, 0.018) 
Follow-upd            
Scheduled 2.67 2.82 -- 3.06 2.92 3.05 3.79 4.36 -- 0.017 (0.011, 0.023) F(1, 4624) = 0.84; 0.359 Unscheduled 0.75 1.11 -- 1.69 1.15 0.96 1.95 2.87 -- 0.016 (0.008, 0.025) 
Main payment sourcee            
Private insurance -- -- 2.09 2.30 2.17 2.45 3.03 3.49 3.88 0.025 (0.019, 0.032) F(1, 4624) = 2.33; 0.127 
Medicare -- -- 4.68 4.66 4.15 3.71 5.23 5.94 5.64 0.020 (0.008, 0.033) F(1, 4624) = 0.56; 0.454 
Medicaid -- -- 2.37 2.69 2.83 2.44 3.36 3.99 3.28 0.017 (0.003, 0.031) F(1, 4624) = 0.05; 0.820 
Self-pay -- -- 4.17 5.07 4.36 5.45 6.07 7.17 6.36 0.036 (0.011, 0.061) F(1, 4624) = 0.50; 0.479 
Otherf -- -- 1.64 2.05 2.57 3.51 2.95 3.97 4.85 0.039 (0.024, 0.055) F(1, 4624) = 0.10; 0.753 
Physician specialty            
Other specialty 0.98 1.22 1.07 1.22 1.04 1.32 1.84 2.11 2.50 0.015 (0.010, 0.019) F(1, 4624) = 3.84; 0.050 
Primary care 3.28 3.68 3.59 3.93 3.98 3.62 4.96 6.18 5.99 0.029 (0.021, 0.036) F(1, 4624) = 2.88; 0.090 
Psychiatry 21.98 17.94 23.61 21.09 20.31 21.99 23.45 23.54 22.82 0.027 (-0.018, 0.071) F(1, 4624) = 0.36; 0.546 
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Diagnosis            
Sleep disorder 23.47 18.44 13.93 17.94 10.70 11.62 11.50 13.38 10.76 -0.071 (-0.128, -0.014) F(1, 4624) = 1.01; 0.314 
Anxiety disorder 32.33 38.02 36.14 34.85 32.18 35.66 34.97 37.82 35.84 0.018 (-0.031, 0.068) F(1, 4624) = 0.23; 0.633 
Mood disorder 25.81 31.85 25.79 24.15 22.90 24.23 26.13 25.67 24.29 -0.024 (-0.078, 0.030) F(1, 4624) = 0.02; 0.884 
nBZRA visits            
Age            
<25 years 0.01 0.01 0.03 0.02 0.06 0.06 0.12 0.09 0.11 0.001 (0.001, 0.002) F(1, 4624) = 107.16; <0.001 
25-44 0.03 0.17 0.14 0.31 0.31 0.63 1.08 1.43 1.01 0.013 (0.011, 0.016) F(1, 4624) = 1.29; 0.255 
45-64 0.04 0.28 0.39 0.54 0.67 0.95 1.67 2.01 2.28 0.024 (0.021, 0.027) F(1, 4624) = 20.88; <0.001 
65+ 0.07 0.23 0.35 0.26 0.58 0.78 1.07 1.38 1.83 0.017 (0.014, 0.020) F(1, 4624) = 0.46; 0.496 
Gender            
Female 0.04 0.16 0.25 0.31 0.47 0.67 1.11 1.35 1.55 0.016 (0.014, 0.018) F(1, 4624) = 2.48; 0.115 Male 0.03 0.19 0.18 0.25 0.33 0.55 0.88 1.13 1.18 0.013 (0.011, 0.014) 
Race            
Non-Hispanic White 0.04 0.19 0.26 0.28 0.44 0.68 1.04 1.42 1.52 0.016 (0.014, 0.017) F(1, 4624) = 6.67; 0.010 
Non-Hispanic Black 0.03 0.08 0.15 0.33 0.16 0.33 0.78 0.83 1.26 0.012 (0.009, 0.015) F(1, 4624) = 2.38; 0.123 
Hispanic 0.04 0.11 0.06 0.19 0.28 0.57 1.02 0.85 1.03 0.012 (0.008, 0.015) F(1, 4624) = 1.84; 0.175 
Other 0.00 0.19 0.07 0.47 0.71 0.49 0.99 0.91 0.62 0.008 (0.004, 0.012) F(1, 4624) = 2.87; 0.090 
Patient status            
New 0.03 0.18 0.24 0.32 0.44 0.66 1.05 1.33 1.50 0.015 (0.014, 0.017) F(1, 4624) = 2.99; 0.084 Established 0.04 0.09 0.08 0.12 0.21 0.37 0.76 0.83 0.75 0.009 (0.007, 0.011) 
Follow-upd            
Scheduled 0.03 0.18 -- 0.30 0.44 0.66 1.06 1.29 -- 0.014 (0.013, 0.016) F(1, 4624) = 3.71; 0.054 Unscheduled 0.03 0.07 -- 0.16 0.13 0.17 0.33 0.83 -- 0.006 (0.003, 0.009) 
Main payment sourcee            
Private insurance -- -- 0.17 0.31 0.39 0.58 1.05 1.33 1.31 0.018 (0.015, 0.020) F(1, 4624) = 0.67; 0.413 
Medicare -- -- 0.41 0.33 0.65 0.81 1.25 1.47 2.01 0.023 (0.018, 0.028) F(1, 4624) = 1.52; 0.218 
Medicaid -- -- 0.15 0.23 0.30 0.51 0.68 0.76 0.71 0.009 (0.005, 0.012) F(1, 4624) = 5.55; 0.019 
Self-pay -- -- 0.30 0.31 0.31 0.63 0.61 1.32 1.53 0.017 (0.010, 0.023) F(1, 4624) = 0.09; 0.765 
Otherf -- -- 0.21 0.21 0.25 0.91 0.73 0.66 0.64 0.008 (0.004, 0.012) F(1, 4624) = 3.30; 0.069 
Physician specialty            
Other Specialty 0.02 0.11 0.11 0.08 0.21 0.26 0.56 0.68 0.84 0.008 (0.007, 0.010) F(1, 4624) = 28.24; <0.001 
Primary care 0.04 0.20 0.29 0.48 0.58 0.96 1.48 1.94 2.15 0.023 (0.019, 0.026) F(1, 4624) = 17.81; <0.001 
Psychiatry 0.22 1.05 1.53 1.57 2.23 2.87 4.13 4.21 3.52 0.039 (0.030, 0.047) F(1, 4624) = 7.20; 0.007 
Diagnosis            
Sleep disorder 2.31 5.70 6.58 13.39 10.42 11.94 13.99 16.60 13.72 0.099 (0.045, 0.153) F(1, 4624) = 1.93; 0.165 
Anxiety disorder 0.27 0.62 1.30 1.13 1.58 2.05 2.90 3.06 2.82 0.028 (0.020, 0.037) F(1, 4624) = 2.00; 0.158 
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Mood disorder 0.51 1.85 2.43 2.47 2.58 3.02 5.55 6.19 3.78 0.042 (0.029, 0.056) F(1, 4624) = 9.38; 0.002 
BZD + nBZRA Visits            
Age            
<25 years 0.00 0.00 0.00 0.03 0.00 0.00 0.01 0.02 0.02 0.000 (0.000, 0.000) F(1, 4624) = 42.30; <0.001 
25-44 0.00 0.04 0.05 0.10 0.12 0.15 0.34 0.45 0.57 0.006 (0.004, 0.007) F(1, 4624) = 1.09; 0.296 
45-64 0.01 0.02 0.07 0.17 0.16 0.20 0.38 0.62 0.58 0.007 (0.005, 0.008) F(1, 4624) = 5.38; 0.020 
65+ 0.01 0.03 0.03 0.01 0.13 0.11 0.18 0.32 0.23 0.003 (0.002, 0.004) F(1, 4624) = 0.02; 0.882 
Gender            
Female 0.01 0.03 0.04 0.08 0.12 0.14 0.28 0.42 0.42 0.005 (0.004, 0.005) F(1, 4624) = 4.13; 0.042 Male 0.00 0.02 0.02 0.08 0.08 0.10 0.16 0.28 0.25 0.003 (0.002, 0.004) 
Race            
Non-Hispanic White 0.01 0.03 0.04 0.08 0.11 0.13 0.25 0.42 0.40 0.004 (0.004, 0.005) F(1, 4624) = 7.74; 0.005 
Non-Hispanic Black 0.00 0.00 0.01 0.17 0.01 0.14 0.18 0.19 0.22 0.002 (0.001, 0.004) F(1, 4624) = 2.97; 0.085 
Hispanic 0.00 0.00 0.02 0.03 0.19 0.08 0.18 0.24 0.21 0.003 (0.001, 0.004) F(1, 4624) = 2.85; 0.091 
Other 0.00 0.01 0.00 0.03 0.00 0.00 0.10 0.15 0.28 0.003 (0.001, 0.004) F(1, 4624) = 3.93; 0.047 
Patient status            
New 0.01 0.03 0.04 0.09 0.11 0.13 0.25 0.39 0.37 0.004 (0.003, 0.005) F(1, 4624) = 2.22; 0.136 Established 0.00 0.01 0.02 0.01 0.04 0.04 0.11 0.19 0.25 0.002 (0.002, 0.003) 
Follow-upd            
Scheduled 0.01 0.03 -- 0.08 0.11 0.12 0.24 0.37 -- 0.004 (0.003, 0.005) F(1, 4624) = 5.18; 0.023 Unscheduled 0.00 0.00 -- 0.15 0.07 0.05 0.01 0.18 -- 0.001 (0.000, 0.003) 
Main payment sourcee            
Private insurance -- -- 0.03 0.07 0.08 0.09 0.23 0.35 0.36 0.005 (0.004, 0.006) F(1, 4624) = 0.01; 0.93 
Medicare -- -- 0.06 0.04 0.15 0.12 0.21 0.37 0.32 0.004 (0.003, 0.006) F(1, 4624) = 0.13; 0.718 
Medicaid -- -- 0.04 0.33 0.18 0.11 0.19 0.26 0.33 0.002 (-0.001, 0.005) F(1, 4624) = 4.35; 0.037 
Self-pay -- -- 0.06 0.07 0.12 0.27 0.24 0.87 0.52 0.009 (0.004, 0.014) F(1, 4624) = 3.48; 0.062 
Otherf -- -- 0.02 0.05 0.05 0.30 0.17 0.24 0.22 0.003 (0.001, 0.005) F(1, 4624) = 0.53; 0.466 
Physician specialty            
Other Specialty 0.00 0.01 0.01 0.02 0.03 0.02 0.08 0.12 0.15 0.001 (0.001, 0.002) F(1, 4624) = 21.51; <0.001 
Primary care 0.01 0.02 0.01 0.12 0.15 0.11 0.20 0.45 0.46 0.005 (0.004, 0.006) F(1, 4624) = 0.02; 0.879 
Psychiatry 0.08 0.42 0.92 0.72 0.95 1.94 3.64 4.10 3.37 0.041 (0.032, 0.051) F(1, 4624) = 20.82; <0.001 
Diagnosis            
Sleep disorder 0.00 1.17 0.00 0.00 0.76 0.61 1.05 3.43 2.70 0.036 (0.019, 0.052) F(1, 4624) = 4.95; 0.026 
Anxiety disorder 0.09 0.60 0.51 1.02 1.26 1.95 4.25 5.08 3.87 0.050 (0.037, 0.063) F(1, 4624) = 19.46; <0.001 
Mood disorder 0.20 0.73 1.28 1.29 1.70 1.69 4.47 4.68 3.26 0.041 (0.030, 0.052) F(1, 4624) = 13.79; <0.001 
Note: Benzodiazepines include: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, temazepam, and triazolam. Non-benzodiazepine 
receptor agonists include: zolpidem, zaleplon, and eszopliclone.   
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a Statistics correspond to the percentage of visits in a specific year that resulted in a prescription for the respective medication within each patient and visit characteristic, and are weighted to make results 
nationally representative. 
b Statistics are from linear probability regression models of absolute change in percentage of patient visits resulting in prescription for respective medications across the entire study period (1993-2010); 
B = beta coefficient for time, 95% CI = 95% Confidence Interval. 
c p-values are from Wald statistics for interaction coefficients of time with the respective patient and visit characteristic vs. all other visits. Adjusted for all patient and visit characteristics. 
d Inquires of follow-up scheduled was not asked in the NAMCS sample of doctors in 1997-1998, as well as 2009-2010. 
e Main payment sources was not assessed in the NAMCS sample of doctors in 1995-1996. 
f Other payment source includes worker compensation, no pay, other, and unknown. 
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Chapter 3: Changes in physician prescribing of 
benzodiazepines and non-benzodiazepine receptor agonists 
between 1993 and 2010 
  
ABSTRACT 
BACKGROUND: Prescribing of benzodiazepines (BZDs) and non-benzodiazepine 
receptor agonists (nBZRAs) has increased over the past two decades, but little is known 
about the reasons for these increases.  The purpose of this study was to investigate 
whether the increase in prescribing of BZDs and nBZRAs could potentially be attributed 
to an increase in the number of physicians prescribing these agents, or an increase in 
prescribing volume per prescribing physician. 
 
METHODS: We used data from 21,860 physicians from the 1993-2010 waves of the 
National Ambulatory Medical Care Survey. We categorized physicians as BZD 
prescribers and as nBZRA prescribers separately if they reported prescribing the 
respective medication during at least one of a series of sampled visits during a randomly 
selected one-week period. We assessed trends in the proportion of physicians prescribing 
these agents using logistic regression and trends in the number of visits in which these 
agents were prescribed per prescribing physician using zero-truncated negative-binomial 
regression models. 
 
RESULTS: Overall, there was an increase over time in the proportion of all physicians 
who were BZD prescribers and nBZRA prescribers.  The proportion of physicians who 
were BZD prescribers increased from 23.8% in 1993-1994 to 44.4% in 2009-2010 (Odds 
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Ratio [OR]=2.51, 95% Confidence Interval [CI]=2.31-2.74) and the proportion of 
physicians who were nBZRA prescribers increased from 1.0% to 25.8% (OR=16.79, 95% 
CI=14.38-19.60).  Among nBZRA prescribers, the predicted number of visits resulting in 
a prescription for an nBZRA increased from 1.33 in 1993-1994 to 1.72 in 2009-2010 
(Incidence Rate Ratio=2.42, 95% CI=1.70-3.44); there was no change in the predicted 
number of visits resulting in a BZD prescription per BZD prescribing physicians. 
 
CONCLUSIONS: The increase in prescribing of BZDs is due to an increase in number 
of prescribers of these medications, but not prescribing volume per prescribing physician.  
The increase in prescribing of nBZRAs is due to increases in both the number of 
prescribers and the prescribing volume of individual prescribers. With the growing 
prescribing of BZDs and nBZRAs, it will be important to educate physicians who 
prescribe these medications on the potential adverse effects associated with the use of 





Pharmacological options for the treatment of insomnia have increased over the 
past two decades. Currently, a number of pharmacological agents to treat insomnia 
exist,1-3 but the most commonly prescribed are benzodiazepines (BZDs) and non-
benzodiazepine receptor agonists (nBZRAs).102,103 BZDs, which were introduced in the 
1960s and have a range of indications including anxiety and sleep disorders, were later 
found to be associated with a number of adverse health outcomes such as falls and hip 
fractures,8,9,33 as well as disability, especially in older adults.10-12,104 The introduction of 
nBZRAs was in part motivated by concern about the dangers of BZDs; however, research 
suggests that these medications might have some of the same harmful side effects as 
BZDs.27,45,50,105,106 
 Despite the concerns regarding adverse side effects, prescribing of BZDs and 
nBZRAs has increased in the past decade.41,70,107,108 Ford et al. found nearly a 300% 
increase in prescriptions for sleep medications from 1999 to 2010.41 Furthermore, it was 
estimated that in 2013 nearly 9 million Americans took medications to help induce 
sleep.107  
These dramatic increases in prescribing of sleep medications are at odds with 
studies showing trends in prevalence of insomnia diagnoses over time. While some 
studies have shown small decreases in the amount of and satisfaction with sleep,109-111 the 
changes in sleep quality are not proportional to the increasing rate in prescribing of sleep-
aids.30,41,70,107,108 For example, a recent study by Moloney et al. showed that prescriptions 
for sleep medications from 1993-2007 far outpaced the rate of diagnosis of insomnia, 
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suggesting that physicians may perhaps be over treating transient or mild sleep 
disturbances with these potentially dangerous medications.30 
 More studies about the role of physicians in the increasing prescription rate of 
these medications are needed.  The increase in prescribing of BZDs and nBZRAs can be 
due to an increase in the number of physicians who prescribe these medications, or an 
increase in the volume of prescribing among physicians who already prescribe these 
medications.  The different reasons for the prescription trends call for different policy 
responses and interventions aimed at reducing potentially unnecessary prescription of 
these hypnotic medications.  To explore the potential reasons for recent trends in 
prescription of BZDs and nBZRAs, we examined trends in the number of prescribing 
physicians and in the number of visits to prescribing physicians in which these 
medications were prescribed over the 1993-2010 period. We also explored variations in 




 Data for this study came from the 1993-2010 waves of the National Ambulatory 
Medical Care Survey (NAMCS). NAMCS is an annual cross-sectional study conducted 
by the National Center for Health Statistics (NCHS) that examines the delivery of 
services in ambulatory healthcare settings in the United States. The study samples 
physicians using a multi-stage probability sampling design based on the American 
Medical Association's Master File. Physicians or their staff were asked to report on 
randomly selected visits to their practices during a random one-week period. The number 
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of physicians who participated each year between 1993 to 2010 ranged from 2,036 to 
3,001, resulting in a combined sample of 21,860 physicians who reported on 516,118 
visits. Physicians in our sample reported on an average of 23.6 visits (standard 
deviation=11.5, range=1-194). The response rates ranged from 60-70% across the years. 
 
Measures 
 Medications. Physicians were asked to report on any medications that were 
ordered or prescribed during each of their sampled visits.  Between 1993 and 2002, 
physicians could report on a maximum of six medications per visit. This maximum was 
increased to eight from 2003 to 2010.  We limited the maximum number of medications 
to six across years to make years comparable. The large majority of visits were 
prescribed less than six medications (median number=1). To assess the impact of the 
decision to limit medications prescribed to 6, we compared the proportion of physicians 
who were categorized as BZD or nBZRA prescribers based on the 6- and 8-medication 
counts for years 2003-2010. The proportions were very similar for both BZD prescribers 
(39.4% vs. 40.8%) and nBZRA prescribers (19.6% vs. 21.0%). BZDs for this study 
comprised alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, 
flurazepam, lorazepam, oxazepam, temazepam, and triazolam. nBZRAs comprised 
zolpidem, zaleplon, and eszopliclone.    
 Age of patient population. Physicians reported on the age of the patient seen at the 
visit.  Based on this, we calculated the percentage of a physician’s sampled visits that 
were for those aged 65 or older and categorized each physician according to whether or 
 39 
not they treated mostly older adults (defined as >50% of their sampled patients being age 
65 or older). 
Physician specialty. Physicians were asked to confirm their specialty listed on the 
AMA Masterfile.  We categorized these specialties as primary care (which included  
“general/family practice” and “internal medicine”), psychiatry, and other specialty. 
Other measures. On induction into the study, physicians reported on the region in 
which they practiced (i.e., Northeast, Midwest, South, and West) and whether their 
practice was in an urban or rural environment. 
 
Analyses 
 Analyses were conducted in two stages. First, we assessed how the proportion of 
physicians who prescribed BZD and nBZRA medications changed over time. We 
dichotomized physicians based on whether or not they prescribed each respective 
medication during at least one of their reported visits. We assessed trends using bivariate 
logistic regression models with time as the predictor and whether or not the physician 
was a BZD or an nBZRA prescriber as the outcome. We repeated these analyses stratified 
by age of the sampled patient population (i.e., ≤50%, >50% over age 65) and by 
physician specialty (i.e., primary care, psychiatry, and other specialty).  To test 
differences in trends across these groups, we introduced interaction terms between the 
year variable and the patient age as well as with physician specialty. A statistically 
significant interaction term would suggest that the trend is different across groups.  We 
then conducted multivariable regression analyses adjusting for patient age and physician 
specialty in addition to region, and urban vs. rural location of the practice. 
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Second, limiting our sample to BZD and nBZRA prescribers respectively, we 
assessed whether the number of visits per prescriber changed over time. Because we 
limited our sample to prescribers of the respective medications for these analyses, none of 
the count of visits had a value of 0, making Poisson or negative-binomial regression 
models inappropriate. We therefore used zero-truncated negative-binomial regression. 
We set the offset variable for these models as the total number of reported visits in which 
a medication was prescribed per physician. In addition, based on the bivariate models, we 
reported at each time point the predicted number of visits in which the medication was 
prescribed among prescribers of the medication respectively. Similar to above, we 
stratified results by the age of the sampled patient population and physician specialty, 
tested for differences in trends across groups using interaction terms, and conducted 
adjusted analyses controlling for the variables mentioned above. 
 As suggested by the NCHS,80 we aggregated time into 2-year bins to enhance 
stability of the estimates and numbered them with values from 1 to 9 (e.g., 1 = “1993-
1994,” 2 = “1995-1996,” etc.). We then transformed this time variable by subtracting 1 
and dividing by 8. The resulting time variable thus ranged from 0 to 1, enabling us to 
interpret the regression coefficients for this variable as change across the entire study 
period. 
 While the NAMCS offers visit-level survey weights to account for the complex 
sample design and make results nationally representative, we did not weight our analyses 
because NAMCS does not provide physician-level weights for all years. As a sensitivity 
analysis, we computed misspecification effects for all statistically significant analyses 
reported here for years 2005-2010, using physician sampling weights for years 2005-
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2010 provided by NAMCS. We multiplied all standard errors from unweighted 
regression models of the main analyses for years 1993-2010 by these misspecification 
effects, assuming that the misspecification effects for all included years were similar to 
those for the 2005-2010 years for which data were available. The results of these 
sensitivity analyses were for the most part similar to those from the unweighted analyses 
(see Supplemental Table 3.1)—we therefore report only the unweighted analyses results 




Trends in proportion of physicians who prescribed BZDs and nBZRAs 
 The proportion of physicians who prescribed BZDs during at least one of their 
reported visits increased from 23.8% (n=713) in 1993-1994 to 44.4% (n=1,144) in 2009-
2010 (Figure 3.1 and Table 3.1, odds ratio [OR]=2.51, 95% Confidence Interval 
[CI]=2.31-2.74). In stratified analyses, all subgroups saw a statistically significant 
increase in proportion of physicians who prescribed BZDs.  The trend was statistically 
significantly stronger for physicians in other specialties (OR=2.84, 95% CI=2.53-3.19) 
and primary care (OR=2.19, 95% CI=1.85-2.59), compared to psychiatry (OR=1.48, 95% 
CI=1.01-2.16).  No trend differences were observed between physicians whose sampled 
visits included mostly older patients compared to other patients. Similar patterns were 
seen after adjustment for potential confounders. 
 The proportion of physicians who prescribed nBZRAs during at least one of their 
reported visits increased from 1.0% (n=29) in 1993-1994 to 25.7% (n=664) in 2009-2010 
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(Figure 3.1 and Table 3.1; OR=16.79, 95% CI=14.38-19.60).  Increases were seen across 
all subgroups analyzed.  The trend was stronger among other specialty (OR=26.39, 95% 
CI=20.59-33.83) compared to primary care (OR=16.31, 95% CI=12.50-21.27) and 
psychiatry (OR=11.79, 95% CI=8.01-17.36).  No differences were observed in trends 
according to the age of patient population.  Similar patterns were seen after adjustment 
for potential confounders. 
 
Trends in number of visits in which a BZD or nBZRA was prescribed among 
prescribers of respective medications 
 Overall, the number of BZD visits increased from 1,875 in 1993-1994 to 3,149 in 
2009-2010 (Figure 3.1).  The predicted number of visits that were BZD visits among 
BZD prescribers remained virtually unchanged from 1993-2010 (Table 3.2). In zero-
truncated negative-binomial regression models, we also observed no increases in this 
trend among most groups except for other specialty (Incidence Rate Ratio [IRR]=1.29, 
95% CI=1.10-1.52) and primary care (IRR=1.63, 95% CI=1.39-1.90).  While the trend 
for primary care was stronger than for “other specialty,” no differences were observed in 
the trends between physicians who mostly saw older patients. After adjustment for 
confounders, the adjusted incidence rate ratio (AIRR) became positive among all 
physicians (AIRR=1.35, 95% CI=1.24-1.47), among physicians whose sampled patients 
were younger (AIRR=1.38, 95% CI=1.26-1.53) as well as physicians most of whose 
sampled patients were 65+ years old (AIRR=1.22, 95% CI=1.01-1.48). In further 
analyses, we found that this discrepancy in magnitude of the AIRR was due to a steeper 
trend in the proportion of BZD prescribing psychiatrists whose sampled patients were 
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younger (from 41.4% in 1993-1994 to 60.8% in 2009-2010 vs. 72.1% in 1993-1994 to 
77.0% in 2008-2010 for psychiatrists overall). 
 The number of nBZRA visits increased from 32 in 1993-1994 to 1,101 in 2009-
2010 (Figure 3.1). The predicted number of visits that were nBZRA visits among nBZRA 
prescribers increased from 1.33 in 1993-1994 to 1.72 in 2009-2010 (IRR=2.42, 95% 
CI=1.70-3.44) (Table 3.2).  An increasing trend was seen across all subgroups analyzed. 
Physicians practicing in primary care saw a greater increase in the average number of 
nBZRA visits (IRR=7.29, 95% CI=4.14-12.83) compared to “other specialty” (IRR=2.76, 
95% CI=1.48-5.15). No differences were observed between physicians according to 
patient age. Results did not change appreciably after adjustment for confounders.   
 
Sensitivity analyses 
 For the main analyses reported above, we categorized physicians as either BZD 
prescribers or nBZRA prescribers based on whether they prescribed the medications in at 
least one visit; however this threshold may have been too low. We therefore conducted 
two series of sensitivity analyses for the analyses on proportion of physicians who 
prescribed these medications: (a) by changing the threshold for categorizing physicians as 
BZD prescribers or nBZRA prescribers to those who prescribed the medications during 
two or more visits, and (b) limiting the sample to physicians who reported on at least 10 
visits. Results from these sensitivity analyses showed a similar positive statistically 
significant trend in the number of physicians prescribing BZDs and nBZRAs (see 




 A number of studies have found that prescribing of BZDs and nBZRAs have 
increased over the past two decades.41,70,107,108 The purpose of this study was to determine 
whether the increase in prescribing of these agents from 1993 to 2010 reflects an increase 
in the number of physicians prescribing these medications, or an increase in the number 
of visits in which these physicians prescribe the medications.  Overall, our study had two 
main findings. 
 First, we found increases in the proportion of physicians who prescribed BZDs 
and those who prescribed nBZRAs.  It is not surprising to see growth in the number of 
nBZRA-prescribing physicians given that this medication class was first introduced in 
1993.  However, the increase in number of BZD prescribers is surprising—particularly in 
light of greater awareness in recent years about the dangers in use of these agents in some 
cases and availability of other pharmacological and non-pharmacological treatments for 
insomnia and anxiety disorders, including nBZRAs for insomnia.8,10,11,33,104 In stratified 
analyses, we found that the increase in BZD prescribers was driven by larger increases 
among physicians in other specialties besides psychiatry, and in primary care.  This 
finding is in line with studies showing increases in psychotropic prescribing in primary 
care practices.112-114 Indeed, Olfson, et al. found that prescribing of BZDs to older adults 
in 2008 was most common among non-psychiatrists.115 Taken together, these findings 
call for programs that educate primary care physicians and other non-psychiatrists on the 
potential adverse effects of these medications. 
 Second, while we found no overall increase in the number of visits in which a 
BZD was prescribed among BZD prescribers, there were significant increases for nBZRA 
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visits among nBZRA prescribers.  With the greater acceptance in prescribing of nBZRAs 
over the past two decades, the frequency of prescribing likely increased as well.  The 
increasing trend was particularly large among doctors in primary care, a finding that 
confirms previous studies showing an increase in prescribing of psychiatric medications 
in primary care offices.114 While we did not see an increase in the number of visits in 
which a BZD was prescribed among BZD prescribers, we did observe a statistically 
significant increase among physicians in other specialties and in primary care. This 
finding suggests that another contributor to the increase in prescribing of BZDs is 
increased volume in prescribing by non-psychiatry physicians. 
 It is interesting to note that we did not observe differences in trends for proportion 
of prescribers and volume per prescriber of BZDs and nBZRAs between physicians 
according to patient age. With the growing awareness among physicians about the 
potential adverse effects of these agents in older adults, it is surprising that physicians 
who saw mostly older adults did not have different trends in prescribing than those seeing 
mostly younger patients.  Numerous clinical guidelines caution against prescribing BZDs 
and other sedatives to older adults;15,57,58 for example, the Beer’s Criteria15 lists both 
BZDs and nBZRAs as potentially dangerous medications that should be avoided when 
prescribing to older adults. 
With the growth in the number of BZD and nBZRA prescribers, it is important 
that efforts be made to communicate best prescribing practices to physicians. A number 
of physician organizations and foundations have introduced guidelines for safe 
prescribing of BZDs and nBZRAs.  For example, the American Psychiatric Association 
provides guidelines on the treatment of Panic Disorder, and suggests that BZDs be used 
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only for short-term treatment.116 The American Academy of Sleep Medicine guidelines 
on the treatment of insomnia suggest that physicians prescribe nBZRAs only as a short-
term treatment if behavioral interventions were not effective.60 Many of these guidelines, 
however, target physicians with specific specialties, and as our study shows, over the 
years there has been a growth in prescribing of BZDs and nBZRAs among many 
physician specialties, including those in primary care and non-psychiatric specialties.  It 
will be important that future guidelines be developed for a broader audience of physicians. 
A number of initiatives to encourage safe prescribing practices of BZDs have 
been introduced.117-119 These include educational material targeting high-volume 
prescribers,62,63 as well as full-fledged audits of medications prescribed by 
physicians.119,120  While research on the efficaciousness of these interventions to reducing 
BZD prescribing is conflicting,121 the most effective interventions appear to include 
combining patient education with pharmacy and physician involvement.120 There have 
been few initiatives to discourage unsafe prescribing of nBZRAs and the impact of 
educational efforts and guidelines on prescription of these medications has rarely been 
examined.  Due to emerging evidence showing nBZRAs to be associated with dangerous 
side effects,27,45,50,105,106 it will be important to develop such interventions for nBZRAs 
and to investigate their impact. 
 There are a number of behavioral treatments for sleep and anxiety disorders that 
have shown to be as effective, if not more so, than BZDs and nBZRAs.98,99 One notable 
example is cognitive behavioral therapy for insomnia (CBT-i), which combines sleep 
restriction therapy,122 stimulus control,123 sleep hygiene education, and relapse prevention 
in regularly scheduled meetings with clinicians.98 While these treatments show promise, 
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adoption of their use has been slow, and the availability of providers trained in these 
methods is limited.124 There are ongoing efforts to implement CBT-i interventions in 
primary care settings,97 which in light of our finding of greater adoption in prescribing of 
BZDs and nBZRAs in primary care will be increasingly important. Furthermore, more 
work is needed to encourage adoption and dissemination of these interventions.  
Insurance reimbursement policies, and educating paraprofessionals on the administration 
of CBT-i could help to address this need.   
This study had a number of limitations.  First, we categorized physicians as BZD 
and nBZRA prescribers based on their sampled visits. It is quite possible that the 
medications prescribed during a physician’s sampled visits were not representative of 
their typical prescribing practices.  For example, physicians who did not prescribe BZDs 
or nBZRAs during the specific sampled visits might have done so in their other visits.  
Therefore some physicians in our sample may have been misclassified as non-prescribers.  
Second, the number of visits in which these medications were prescribed per prescriber 
could have varied over the years. However, past research suggests a remarkable degree of 
brand loyalty in prescription practices of physicians.125 Thus, it is quite likely that their 
prescribing behaviors had remained consistent across sampled and non-sampled visits.  
Finally, we did not use physician-level survey weights in our analyses as they were not 
available for all years, and therefore the estimates may not be nationally representative.  
However, our sensitivity analyses using misspecification effects suggest that our 
inferences would have changed little if we had used physician-level survey weights. 
In the context of these limitations, our study provides a broad overview of the 
ways in which physician prescribing practices may have contributed to the increasing 
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trends in prescription of BZDs and nBZRAs.  We found that the growth in prescribing of 
BZDs is due to a greater number of physicians prescribing these medications, particularly 
among primary care and non-psychiatric specialties; whereas, the growth in prescribing 
of nBZRAs is due to increases in both the number of nBZRA prescribers and the number 
of visits in which they prescribe these medications (particularly among primary care 
physicians). Future research should investigate ways to educate new prescribers of BZDs 
and nBZRAs on these medications’ potential risks and encourage the adoption and 
dissemination of safer behavioral treatments for sleep and anxiety disorders. 
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Figure 3.1: Trends in physician prescribing of benzodiazepines and non-benzodiazepine 
receptor agonists, National Ambulatory Medical Care Survey 1993-2010 
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Table 3.1: Trends in proportion of physicians who prescribed BZDs and nBZRAs from 1993-2010, National Ambulatory Medical 
Care Survey 
















































AORc (95% CI) 
BZDs            
All physicians 23.8 27.9 27.6 28.5 29.6 30.3 39.2 42.7 44.4 2.51 (2.31, 2.74) 2.55 (2.33, 2.80) 
>50% patients age 65+            
No 23.0 26.8 26.5 28.1 28.9 30.4 39.3 41.9 43.1 2.58 (2.34, 2.83) 2.53 (2.28, 2.81) 
Yes 27.9 34.0 33.0 30.9 32.9 30.0 38.6 46.4 50.3 2.23 (1.82, 2.73) 2.56 (2.07, 3.16) 
Specialty            
Other specialty 16.5 16.3 17.8 18.0 18.9 19.2 28.1 31.0 34.5 2.84 (2.53, 3.19) 2.79 (2.48, 3.13) 
Primary care 44.3 47.6 43.0 48.9 49.7 49.6 57.9 61.4 62.3 2.19 (1.85, 2.59)d 2.32 (1.96, 2.75) 
Psychiatry 72.1 72.5 73.9 76.2 80.4 78.9 76.2 80.7 77.0 1.48 (1.01, 2.16)d 1.49 (1.02, 2.18)d 
nBZRAs            
All physicians 1.0 3.6 5.2 6.0 9.3 11.7 17.5 22.2 25.7 16.79 (14.38, 19.60) 19.34 (16.40, 22.80) 
>50% patients age 65+            
No 1.0 3.4 4.9 6.5 9.3 11.7 17.4 21.7 25.1 16.46 (13.88, 19.51) 18.66 (15.54, 22.40) 
Yes 0.8 4.7 6.7 3.8 9.8 11.9 18.5 24.4 28.6 18.40 (12.71, 26.63) 21.29 (14.54, 31.15) 
Specialty            
Other specialty 0.6 1.5 2.5 2.6 5.0 5.7 11.0 15.3 18.3 26.39 (20.59, 33.83) 25.72 (20.02, 33.03) 
Primary care 2.0 5.6 7.2 11.3 14.5 19.6 26.4 32.3 37.1 16.31 (12.50, 21.27)d 16.77 (12.82, 21.94)d 
Psychiatry 3.7 17.1 25.4 26.2 39.2 44.6 46.4 49.3 59.5 11.79 (8.01, 17.36)d 12.04 (8.16, 17.78)d 
Note: BZD prescribers include those who prescribed any of the following medications: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, 
temazepam, and triazolam. nBZRA prescribers include those who prescribed any of the following: zolpidem, zaleplon, and eszopliclone; OR=odds ratio, 95% CI= 95% confidence interval. 
a Statistics correspond to the percentage of physicians in a specific year that had prescribed the respective medication within strata. 
b Odds ratios come from logistic regression models and correspond to the difference in odds of being a prescriber of the respective medication across the entire study period (i.e., 1993-2010). 
c Adjusted for >50% sampled patients age 65+, specialty, region, and urban/rural setting. 





Table 3.2: Trends in predicted number of prescriptions over sampled visits for physicians who prescribe BZDs and nBZRAs from 
1993-2010, National Ambulatory Medical Care Survey 




























































AIRRc (95% CI) 
BZDs            
All physicians 2.67 2.68 2.69 2.69 2.70 2.71 2.71 2.72 2.73 1.04 (0.91, 1.18) 1.35 (1.24, 1.47) 
>50% patients age 65+            
No 2.82 2.82 2.83 2.83 2.83 2.84 2.84 2.85 2.85 1.02 (0.88, 1.18) 1.38 (1.26, 1.53) 
Yes 2.10 2.11 2.13 2.14 2.15 2.17 2.18 2.20 2.21 1.10 (0.90, 1.35) 1.22 (1.01, 1.48) 
Specialty            
Other specialty 1.86 1.89 1.92 1.94 1.97 2.00 2.03 2.06 2.10 1.29 (1.10, 1.52) 1.26 (1.07, 1.48) 
Primary care 1.93 1.99 2.05 2.12 2.19 2.27 2.34 2.43 2.52 1.63 (1.39, 1.90)d 1.75 (1.50, 2.04)d 
Psychiatry 5.47 5.53 5.58 5.64 5.70 5.76 5.81 5.87 5.93 1.09 (0.95, 1.26) 1.10 (0.96, 1.27) 
nBZRAs            
All physicians 1.33 1.36 1.40 1.44 1.49 1.54 1.59 1.65 1.72 2.42 (1.70, 3.44) 3.83 (2.80, 5.24) 
>50% patients age 65+            
No 1.37 1.41 1.45 1.49 1.53 1.58 1.64 1.69 1.76 2.20 (1.50, 3.25) 3.64 (2.58, 5.14) 
Yes 1.13 1.16 1.19 1.23 1.27 1.33 1.40 1.49 1.59 4.38 (2.08, 9.23) 4.86 (2.27, 10.40) 
Specialty            
Other specialty 1.18 1.21 1.23 1.26 1.30 1.33 1.37 1.42 1.47 2.76 (1.48, 5.15) 2.85 (1.52, 5.35) 
Primary care 1.09 1.12 1.15 1.20 1.26 1.33 1.42 1.55 1.71 7.29 (4.14, 12.83)d 6.77 (3.87, 11.87)d 
Psychiatry 1.57 1.66 1.76 1.87 2.01 2.16 2.34 2.54 2.77 3.08 (1.91, 4.98) 3.15 (1.96, 5.08) 
Note: BZD prescribers include those who prescribed any of the following medications: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, 
temazepam, and triazolam. nBZRA prescribers include those who prescribed any of the following: zolpidem, zaleplon, and eszopliclone; OR=odds ratio, 95% CI= 95% confidence interval. 
a Statistics correspond to the predicted number of visits with a prescription for the respective medication within strata, and are estimated from the unadjusted zero-truncated negative-binomial models. 
b Incidence rate ratios, correspond to the change in incidence of prescriptions of the respective medication across the entire study period (i.e., 1993-2010). Estimated using zero-truncated negative-
binomial models. 
c Adjusted for >50% patients age 65+, specialty, region, and urban/rural setting. 




Supplemental Table 3.1: Sensitivity analyses of standard errors for bivariate analyses between 1993 and 2010 accounting for 
misspecification effects calculated from weighted analyses for the years 2005-2010, National Ambulatory Medical Care Survey 


















on revised SEd 
BZDs         
All physicians 1.29 0.11 0.14 <0.001 n.s.    
>50% patients age 65+         
No 1.28 0.12 0.16 <0.001 n.s.    
Yes 1.30 0.23 0.30 <0.001 n.s.    
Specialty         
Other specialty 1.47 0.17 0.25 <0.001 1.06 0.11 0.11 0.004 
Primary care 1.18 0.19 0.22 <0.001 1.29 0.13 0.17 <0.001 
Psychiatry 1.09 0.29 0.31 0.065 n.s.    
nBZRAs         
All physicians 1.33 1.33 1.76 <0.001 0.97 0.44 0.42 <0.001 
>50% patients age 65+         
No 1.26 1.43 1.81 <0.001 1.02 0.44 0.44 <0.001 
Yes 1.34 3.47 4.67 <0.001 1.08 1.67 1.80 <0.001 
Specialty         
Other specialty 1.33 3.34 4.44 <0.001 0.92 0.86 0.80 <0.001 
Primary care 1.23 2.21 2.73 <0.001 1.06 2.10 2.23 <0.001 
Psychiatry 1.06 2.33 2.46 <0.001 1.01 0.75 0.76 <0.001 
Note: Misspecification effects were only computed for statistics for which were statistically significant in main analyses; SE = standard error, n.s. = main analysis not statistically significant; BZD 
prescribers include those who prescribed any of the following: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, temazepam, and 
triazolam. nBZRA prescribers include those who prescribed any of the following: zolpidem, zaleplon, and eszopliclone. 
a Analyses correspond to the bivariate analyses seen in Table 3.1. 
b Analyses correspond to the bivariate analyses seen in Table 3.2; only among BZD prescribers and nBZRA prescribers respectively. 
c Revised SE is calculated by multiplying the misspecification effect with the unweighted SE. 
d p-value corresponds to significance levels for unweighted analyses accounting for misspecification effects. 
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Supplemental Table 3.2: Sensitivity analyses for analyses about trends in proportion of physicians who prescribe BZDs and those 
who prescribe nBZRAs from 1993-2010, National Ambulatory Medical Care Survey 
















































AORc (95% CI) 
BZDs            
(a) prescribers defined 
as those who prescribed 
medication at 2+ visits 
7.4 7.8 8.9 9.5 9.2 9.8 12.2 14.9 16.6 2.49 (2.19, 2.84) 2.72 (2.36, 3.15) 
(b) limiting sample to 
physicians who 
reported on 10+ visits 
23.8 27.9 27.6 28.5 29.6 30.3 39.2 42.7 44.4 2.57 (2.35, 2.81) 2.63 (2.38, 2.89) 
nBZRAs            
(a) prescribers defined 
as those who prescribed 
medication at 2+ visits 
0.0 0.4 0.4 0.3 0.7 1.3 2.6 3.6 4.5 34.84 (22.05, 55.03) 42.93 (26.38, 69.84) 
(b) limiting sample to 
physicians who 
reported on 10+ visits 
1.0 3.6 5.2 6.0 9.4 11.7 17.5 22.2 25.8 17.13 (14.61, 20.07) 20.64 (17.40, 24.48) 
Note: BZD prescribers include those who prescribed any of the following medications: alprazolam, clonazepam, chlorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, 
temazepam, and triazolam. nBZRA prescribers include those who prescribed any of the following: zolpidem, zaleplon, and eszopliclone; OR=odds ratio, 95% CI= 95% confidence interval. 
a Statistics correspond to the percentage of physicians in a specific year that had prescribed the respective medication. 
b Odds ratios come from logistic regression models and correspond to the difference in odds of being a prescriber of the respective medication across the entire study period (i.e., 1993-2010). 
c Adjusted for >50% of physician’s sampled patients age 65+, specialty, region, and urban/rural. 
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Chapter 4: Emergency department visits involving 
benzodiazepines and non-benzodiazepine receptor agonists: 
results from the Drug Abuse Warning Network 
 
ABSTRACT 
BACKGROUND: Benzodiazepines (BZDs) and non-benzodiazepine receptor agonists 
(nBZRAs) are known to be associated with adverse health outcomes necessitating 
treatment in emergency departments (EDs).  The purpose of the study was to assess 
outcomes from visits to EDs attributed to use of BZDs and/or nBZRAs. 
 
METHODS: Data came from the 2004-2011 waves of the Drug Abuse Warning 
Network, a surveillance system that monitors ED visits involving both illicit substances 
and medications used medically and non-medically. We categorized visits as involving a 
BZD without an nBZRA, an nBZRA without a BZD, a BZD + nBZRA, or neither drug 
class. Based on the visit’s disposition, we also categorized visits as resulting in a more 
serious outcome (i.e., hospitalization, patient transfer, or death) or a less serious outcome 
(i.e., discharge home, release to police/jail, or referral to other treatment). Using logistic 
regression, we estimated whether the medications involved (with neither BZDs nor 
nBZRAs as the reference) predicted whether the visit resulted in a more serious outcome 
(vs. less serious outcome).  Results were weighted to be nationally representative of ED 
visits in the United States involving medications or illicit substances. 
 
RESULTS: Compared to visits involving other substances, visits involving BZDs 
without nBZRAs had a 34% greater odds of a more serious outcome (odds ratio 
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[OR]=1.34, 95% Confidence Interval [CI]=1.20-1.50), and visits involving BZDs + 
nBZRAs had three times the odds of a more serious outcome (OR=3.15, 95% CI=2.01-
4.94). Controlling for age, gender, race, the number of reported substances used, whether 
or not alcohol was involved, and study year did not appreciably change the results. 
 
CONCLUSIONS: ED visits involving BZDs and nBZRAs are associated with a greater 
odds of more serious outcomes compared to visits involving neither medication.  Future 
research should examine the factors that contribute to patients experiencing adverse 




Prescribing of sedative-hypnotic medications has increased over the past two 
decades.41,70 Benzodiazepines (BZDs) were developed in the 1950s, and are commonly 
prescribed for the treatment of anxiety disorders and insomnia.34 Non-benzodiazepine 
receptor agonists (nBZRAs) were introduced in the 1990s, and are indicated for the short-
term treatment of insomnia.3 Despite these medications’ popularity, their safety has been 
questioned.  Observational studies have shown BZDs to be associated with a number of 
adverse clinical outcomes, including falls and hip fractures,6,126,127 and functional 
decline.11 For example, Ray et al. found that use of long-acting BZDs was associated 
with a 70% greater odds of experiencing a hip fracture.33 Additionally, recent studies 
have shown nBZRAs to be associated with an increased risk of hip fracture27,45 and 
impaired balance.26,49,51 Older adults are at particularly high risk for adverse health 
outcomes from BZD use.11,128 
In addition to studies demonstrating an association between use of BZDs and 
nBZRAs and adverse clinical outcomes, a number of studies have demonstrated that the 
use of these agents often leads to injuries necessitating emergency treatment.46,129 For 
example, use of BZDs and nBZRAs has been shown to induce severe next-day 
drowsiness that impairs driving abilities.52,55,130 In fact, there have been a number of high 
profile auto accidents in which BZDs and nBZRAs were implicated as a contributing 
factor.76,77 
Studies have also shown that the number of emergency department (ED) visits 
involving BZDs32 as well as nBZRAs31 has increased over the past decade.  For example, 
one study showed ED visits involving zolpidem increased 220% from 2005-2010.31 
 57 
However, little is known about outcomes of these visits. EDs see a broad range of cases, 
both resulting in serious outcomes such as hospitalization or death, and less serious 
outcomes such as being discharged home, and the nature of these outcomes warrants 
further investigation. Additionally, given that older adults are at greater risk for 
hospitalization following ED visits compared to younger people,31 and the large body of 
research investigating the association between BZDs and nBZRAs with adverse health 
outcomes among older people, more research is needed to determine whether any 
differences in the ED-related outcomes are seen across age groups. 
The purpose of this study was to examine outcomes of ED visits involving BZDs 
and nBZRAs. Specifically, we aimed to determine whether visits involving BZDs 
without nBZRAs, nBZRAs without BZDs, and BZDs + nBZRAs were associated with 
more serious outcomes compared to visits involving other substances, and whether these 




 Data for this study came from the 2004-2011 waves of the Drug Abuse Warning 
Network (DAWN).131 DAWN is a surveillance system conducted by SAMHSA that 
monitors substance involved emergency department visits in a nationally representative 
sample of hospitals in the United States.  For an ED visit to be eligible for DAWN, a 
substance must have caused or been a contributing factor for the visit. Substances are 
defined broadly and encompassed both illicit drugs and pharmaceutical agents used both 
medically and non-medically. Hospitals were not asked to list all medications currently 
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taken by the patient—only those that were causes of the visit. Based on medical records, 
staff at participating hospitals reported a number of visit characteristics, including patient 
demographics, the substances involved, the reason for the visit, and the disposition after 
discharge (see below). DAWN provides survey design variables and weights to enable 
researchers to derive nationally representative estimates of ED visits involving substances. 
 
Visits examined in this study 
 If a visit was deemed eligible for inclusion in DAWN, hospital staff were asked to 
categorize the reason for each visit. Because visits could have more than one reason, an 
algorithm was devised to assign a visit type and is described elsewhere.132 Broadly, visits 
were classified as being due to a suicide attempt, seeking detox, alcohol involvement (for 
patients <21 years old), adverse reaction, overmedication, malicious poisoning, 
accidental ingestion, and “other.” To ensure that the visits of our study were due to 
medical use of a pharmaceutical medication, we limited the sample of visits for our 
analyses to those that were due to an adverse reaction or overmedication, and that were 
due to a pharmaceutical agent. We excluded visits involving pharmaceuticals that were 
taken for non-medical reasons (e.g., opiates for patients seeking detox), and for visits in 
which the patient was <12 years old.  Of the 2,272,434 visits reported to DAWN from 
2004-2011, 761,475 (33.5%) met our eligibility requirements.  
 
Measures 
 Substances. Hospital staff reported the names and route of administration of the 
substances involved in the ED visit. Staff also reported whether the case involved alcohol.  
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DAWN categorized each substance using Multum Lexicon drug vocabulary modified to 
include illicit substances. For the purposes of this study, the BZD category included 
alprazolam, clonazepam, clorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, 
lorazepam, oxazepam, temazepam, and triazolam. nBZRAs consisted of zolpidem, 
zaleplon, and eszopiclone. 
 Disposition. Hospital staff also reported the disposition of the visit.  Specifically, 
they recorded whether the visit resulted in the patient being treated and released (i.e., 
discharged home, released to police, or referred to detox treatment), admitted to this 
hospital (i.e., ICU/critical care, surgery, chemical dependency/detox, psychiatric unit, or 
other inpatient unit), and other disposition (i.e., transferred, left against medical advice, 
died, other, and not documented).  Based on a previous study,133 we categorized visits as 
resulting in a more or less serious outcome.  We considered visits resulting in admittance 
to any department in the hospital, patient transfer, or death as a “more serious outcome.” 
We considered ED visits resulting in a discharge home, release to police/jail, or referral 
to other treatment as a “less serious outcome.” The remaining dispositions (including left 
against medical advice, other, and not documented) were not included in our outcome 
variable.   
 Other variables. DAWN also collected limited data on patient characteristics, 
including age (which we categorized as 12-34, 35-44, 45-64, and 65+ years), gender, and 
race (non-Hispanic white, non-Hispanic black, any Hispanic or Latino, and any other 




 For our analyses we combined DAWN data for years 2004-2011.  Each ED visit 
was categorized as involving one or more BZD without nBZRA, one or more nBZRA 
without BZD, any BZD + any nBZRA, and any other substance.  We first examined 
demographic characteristics of patients across ED visits, calculating the proportion of 
patients with each characteristic for visits in the four medication groups. Statistically 
significant differences across medication groups were determined using chi-squared tests.   
 Next, we assessed the association between the medications involved in the visit 
and the visit outcome (more vs. less serious outcome) using logistic regression.  The 
outcome for these analyses was whether the visit resulted in a more or less serious 
outcome with less serious outcome being the reference. The medication group involved 
in the visit served as the predictor, with any other substance involved serving as the 
reference group. 
We conducted unadjusted bivariate as well as multivariable analyses adjusting for 
age, gender, and race of patient, the involvement of alcohol, and number of substances 
involved.  In order to adjust for any possible changes over the 8 years of DAWN, we also 
adjusted for the year of the study, coded as 7 dummy variables (no dummy included for 
2004 which served as the reference). Finally, to determine differences in these trends by 




 Over half of our sample visits were for patients aged 45 years or older (62.3%).  
Females comprised 62.6% of the sample, and the majority of visits were by non-Hispanic 
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white patients (76.3%).  A small minority of visits involved alcohol (1.4%).  Visits 
involved a mean number of 1.36 substances (standard deviation=1.04, range=1-22). 
Across our sample of visits, 2.5% involved BZDs without nBZRAs, 0.7% involved 
nBZRAs without BZDs, and 0.1% involved BZDs + nBZRAs.  Across these medication 
groups (Table 4.1), visits differed by age categories, race, involvement of alcohol, and 
number of substances (all p’s <0.001).  There were no differences by gender. 
 
Visits involving BZDs and nBZRAs and severity of outcomes 
 Twenty three percent of visits in our sample resulted in a more serious outcome 
(vs. less serious outcome).  In unadjusted analyses (Table 4.2), visits involving BZDs 
without nBZRAs had a 34% increased odds of resulting in a more serious outcome 
compared to visits involving other substances (odds ratio [OR]=1.34, 95% confidence 
interval [CI]=1.20-1.50). In addition, visits involving BZDs + nBZRAs had over three 
times the odds of resulting in a more serious outcome compared to visits involving other 
substances (OR=3.15, 95% CI=2.01-4.94). In multivariable-adjusted analyses, visits 
involving BZDs without nBZRAs had a 19% greater odds (AOR=1.19, 95% CI=1.06-
1.34), and visits involving BZDs + nBZRAs had more than 2.5 times the odds 
(AOR=2.63, 95% CI=1.47-4.70) of resulting in a severe outcome compared to visits 
involving other substances. In these analyses, visits involving nBZRAs without BZDs 
showed a 31% decrease in the odds of resulting in a more serious outcome (AOR=0.69, 
95% CI=0.57-0.83) compared to visits involving other substances.  
 Across patient age strata, results were somewhat similar (Table 4.3). In bivariate 
analyses, most age strata had a greater odds of a more serious outcome for visits 
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involving BZDs without nBZRAs compared to visits involving other substances, but the 
magnitude of these variations decreased with increasing age strata. Visits involving BZDs 
+ nBZRAs also showed a greater odds of experiencing a more serious outcome across all 
age strata compared to visits involving neither. While in all age strata, there were odds 
ratios below 1 for nBZRAs without BZDs, this was statistically significant in the 65+ 
years age group.  In multivariate analyses, the associations described above attenuated 
but remained in the same direction. Notably in these analyses, the odds ratio for nBZRAs 
without BZDs for the 45-64 years age group became statistically significant, and the odds 
ratios for BZDs without nBZRAs and BZDs + nBZRAs in the 45-64 years age group, as 
well as BZDs + nBZRAs for the 65+ years age group, all lost statistical significance. 
 
Sensitivity analyses 
 To determine whether the combination of BZDs + nBZRAs during a visit put 
patients at risk for a more serious outcome beyond the combination of any other 
medications they were taking, we conducted a sensitivity analysis in which we limited 
our sample to visits involving two or more substances (Supplemental Table 4.1). The 
sample size for these analyses was 145,667 visits (19.1% of our original analysis sample).  
Compared to visits involving other substances, visits involving BZDs without nBZRAs 
were associated with a 24% greater odds of a more serious outcome (OR=1.24, 95% 
CI=1.09-1.42), and visits involving BZDs + nBZRAs were associated with more than 2.5 
times the odds of a more serious outcome (OR=2.62, 95% CI=1.67-4.12).  Visits 
involving nBZRAs without BZDs had a 36% decline in the odds of resulting in a more 
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serious outcome compared to visits involving neither (OR=0.64, 95% CI=0.49-0.84). 
Results were similar after adjustment for confounders. 
 
DISCUSSION 
 The purpose of this study was to examine the severity of outcomes of emergency 
department visits involving BZDs and nBZRAs.  We found that visits involving BZDs 
and/or nBZRAs were associated with a greater odds of more serious outcomes, compared 
to visits involving any other substance. Compared to visits involving other substances, 
odds for more serious outcomes were greater for visits involving BZDs without nBZRAs, 
and especially visits including both BZDs + nBZRAs. We also found that these same 
results were seen across age groups. 
 The higher odds of a more serious outcome for visits involving BZDs + nBZRAs 
is particularly concerning. We found that visits involving BZDs + nBZRAs were 
associated with a greater risk of a more serious outcome, even after accounting for the 
involvement of alcohol and the number of substances involved. Studies have shown that 
the involvement of alcohol with other sedating agents is associated with adverse health 
outcomes.134 Additionally, polypharmacy has also been shown to be a contributing factor 
to adverse events.101 Surprisingly, in sensitivity analyses limited to visits involving two or 
more substances, the associations we observed remained statistically significant, 
suggesting that the odds for a more serious outcome associated with the combination of 
BZDs and nBZRAs (in addition to BZDs without nBZRAs) is greater than the odds due 
to combination of any two or more other medications.  Several studies have observed 
adverse health outcomes associated with the combined use of BZDs and nBZRAs.75,135,136 
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Our study confirms these findings, and highlights that these outcomes are severe enough 
to necessitate prolonged health service use. 
A plethora of studies show older adults to be at risk for serious outcomes due to 
medication errors.137 That we found an elevated odds for more serious outcomes for visits 
involving BZDs + nBZRAs in the 65+ years age group suggests that the odds of serious 
outcomes due to these medications is even more elevated in this demographic group. A 
number of clinical guidelines list medications that should not be used by older adults.  
For example, the Beers Criteria,57 most recently updated in 2012,15 lists both BZDs and 
nBZRAs as potentially dangerous medications.  Given results from our study, these 
clinical guidelines should also warn against combined use of BZDs and nBZRAs. 
 It was puzzling that visits involving nBZRAs without BZDs had lower odds of 
resulting in a more serious outcome compared to visits involving any other substance, 
after adjustment for confounders. This finding may be due to the greater severity of 
outcomes associated with other substances that comprised the comparison group (i.e. 
visits for which neither a BZD nor nBZRA was involved). These comparison substances 
included prescribed opioids as well as a broad range of other medications associated with 
severe ED outcomes.  
 Regardless of the severity of ED outcomes, visits involving BZDs and/or 
nBZRAs in ED settings highlight the burden these medications place on our healthcare 
system. Studies have found that adverse events due to medication errors are common69 
and it was estimated that medication errors cost the healthcare system $17.8 billion in 
2008.138 Any measures enacted that prevent excess health service use due to medication 
errors could have a drastic impact on lowering healthcare costs. 
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There are promising alternative behavioral treatments for both anxiety disorders 
and insomnia that have been shown to be as effective, if not more effective, than 
treatment with BZDs and nBZRAs, and resulting in fewer side effects.1,2 Examples of 
behavioral insomnia treatments include sleep restriction,122 stimulus control therapy,123 
sleep hygiene education,123 and cognitive behavioral therapy for insomnia.98,139 Cognitive 
Behavioral Therapy99 with and without exposure therapy140 are also common and 
effective non-pharmacological treatments for anxiety disorders. Guidelines encourage the 
use of these treatments,59,60,83 but they are not widely available.124 Efforts to encourage 
adoption of these therapies may help decrease ED use due to use of sedating medications. 
The broader use of selective serotonin reuptake inhibitors for treatment of anxiety 
disorders in recent years141 may also prove to be a safer alternative than long-term BZD 
use for treatment of anxiety disorders.  
 Policy initiatives, as well as patient education campaigns, have sought to decrease 
the prescribing of BZDs and nBZRAs. For example, New York state implemented a 
triplicate prescription monitoring program that resulted in a decline in prescribing of 
BZDs by half.61 Studies have evaluated educational visits to doctors to discuss alternative 
treatments for sleep disorders62 and electronic medical record systems have implemented 
reminders to encourage safer medication alternatives.64 Pamphlets targeted at patients 
have also sought to provide education on proper sleep hygene.142 These efforts need 
further evaluation. 
 Our study has several limitations. First, visits reported in DAWN are not 
representative of all ED visits in the United States—they only represent visits for which 
substances were causes of or contributing factors for the visit. Consequently, we were 
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unable to make comparisons to visits in which no medication was involved.  Second, data 
were reported by hospital staff and based on medical records, potentially resulting in 
useful information not being recorded. For example, we were not able to control for the 
number of previous ED visits because this was not ascertained. Third, we did not know 
the indication for the BZD and/or nBZRA use. The indications may be associated with 
differences in outcomes—for example, ED visits due to BZDs prescribed for transient 
insomnia may have different outcomes than ED visits due to BZD use for chronic anxiety 
disorders. Finally, we did not have information on all medications prescribed to the 
patient—DAWN only reports substances that were involved in the specific visit.  DAWN 
reports depend on ED physicians’ recognition that the medication was a contributing 
factor to the visit. 
Despite our study’s limitations, the findings highlight the potential dangers in use 
of BZDs and nBZRAs.  The study also highlights the consequences of combining BZDs 
with nBZRAs. Efforts should be made to reduce combined use of BZDs and nBZRAs. 
Future studies could also examine the contributing factors that lead patients to experience 
adverse health outcomes due to use of these agents. By doing so, we could substantially 
decrease the burden of preventable adverse outcomes from BZD and nBZRA use, 
potentially resulting in substantial savings on healthcare costs. 
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Table 4.1: Demographic characteristics of patients during emergency department visits 
involving benzodiazepines (BZDs) and non-benzodiazepine receptor agonists (nBZRAs), 































Age     <0.001 
12-34 186,064 (24.5) 4,183 (21.9) 816 (19.5) 157 (21.7)  
35-44 99,418 (12.7) 2,968 (16.1) 629 (11.2) 142 (12.0)  
45-64 221,071 (28.8) 6,101 (33.2) 1,670 (33.0) 354 (41.1)  
65+ 231,223 (34.0) 4,533 (28.8) 1,933 (36.3) 213 (25.2)  
Gender     0.498 
Male 275,227 (37.4) 6,754 (36.1) 1,926 (39.3) 278 (34.2)  
Female 462,234 (62.6) 11,020 (63.9) 3,122 (60.8) 588 (65.9)  
Race/ethnicity     <0.001 
Non-Hispanic 
white  367,398 (76.0) 10,964 (83.8) 2,912 (85.6) 574 (90.1)  
Non-Hispanic 
black 114,985 (14.1) 1,762 (9.4) 407 (6.8) 56 (1.5)  
Hispanic 74,914 (7.8) 1,460 (5.5) 438 (5.9) 62 (7.1)  
All other 
races/ethnicities 19,072 (2.1) 262 (1.3) 123 (1.8) 12 (1.3)  
Alcohol involved     <0.001 
No 727,622 (98.8) 16,007 (91.9) 4,558 (91.6) 793 (93.5)  
Yes 10,153 (1.2) 1,778 (8.1) 490 (8.5) 73 (6.6)  
# substances, 
mean (SD) 1.30 (0.85) 3.34 (2.87) 2.14 (2.04) 6.56 (3.61) <0.001 
Note: BZDs = benzodiazepines (include alprazolam clonazepam clorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, 
lorazepam, oxazepam, temazepam, and triazolam), nBZRAs = non-benzodiazepine receptor agonists (include zolpidem, zaleplon, and 
eszopiclone). 
a All columns report column percentages, unless otherwise reported.  All estimates are weighted to account for oversampling and yield 
nationally representative estimates. 





Table 4.2: Severity of outcome following emergency department visits involving 
benzodiazepines (BZDs) and non-benzodiazepine receptor agonists (nBZRAs), Drug 




















AOR (95% CI) 
Other substances 521,617 (77.4) 201,666 (22.6) Ref. Ref. 
BZDs w/out nBZRAs 11,886 (71.8) 5,329 (28.2) 1.34 (1.20, 1.50) 1.19 (1.06, 1.34) 
nBZRAs w/out BZDs 3,581 (79.8) 1,325 (20.2) 0.87 (0.73, 1.04) 0.69 (0.57, 0.83) 
BZDs + nBZRAs 507 (52.0) 333 (48.0) 3.15 (2.01, 4.94) 2.63 (1.47, 4.70) 
Note: OR=odds ratio, AOR=adjusted odds ratio, 95% CI=95% confidence interval, BZDs=benzodiazepines (include alprazolam 
clonazepam clorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, temazepam, and triazolam), 
nZBRAs=non-benzodiazepine receptor agonists (include zolpidem, zaleplon, and eszopiclone). 
a “More serious outcome” defined as the emergency room visit resulting in an admittance to any department in hospital (i.e., intensive 
critical care unit, surgery, chemical dependence detox/psychiatry, other inpatient unit), transferred, or died. “Less serious outcome” 
defined as an emergency room visit resulting in a discharge home, release to police/jail, or referred to other treatment. 







Table 4.3: Emergency department visits involving benzodiazepines (BZDs) and non-
benzodiazepine receptor agonists (nBZRAs) and severity of disposition following visit 




















AOR (95% CI) 
12-34 years     
Other substances 165,115 (93.0) 17,325 (7.0) Ref. Ref. 
BZDs w/out nBZRAs 3,362 (86.7) 666 (13.3) 2.04 (1.54, 2.69) 1.57 (1.20, 2.05) 
nBZRAs w/out BZDs 712 (95.2) 81 (4.8) 0.67 (0.34, 1.30) 0.63 (0.30, 1.32) 
BZDs + nBZRAs 121 (53.9) 31 (46.1) 11.41 (2.24, 58.14) 6.93 (1.34, 35.75) 
35-44 years     
Other substances 81,624 (88.1) 15,596 (11.9) Ref. Ref. 
BZDs w/out nBZRAs 2,261 (78.8) 588 (21.2) 1.99 (1.28, 3.08) 1.81 (1.07, 3.05) 
nBZRAs w/out BZDs 499 (89.0) 110 (11.0) 0.92 (0.50, 1.68) 0.81 (0.41, 1.61) 
BZDs + nBZRAs 97 (58.9) 38 (41.1) 5.16 (1.85, 14.37) 4.35 (1.34, 14.18) 
45-64 years     
Other substances 154,362 (77.3) 61,736 (22.7) Ref. Ref. 
BZDs w/out nBZRAs 3,981 (69.6) 1,919 (30.4) 1.49 (1.27, 1.73) 1.18 (0.98, 1.44) 
nBZRAs w/out BZDs 1,236 (81.5) 386 (18.5) 0.77 (0.55, 1.09) 0.63 (0.43, 0.91) 
BZDs + nBZRAs 198 (59.4) 145 (40.6) 2.33 (1.09, 4.97) 1.49 (0.72, 3.06) 
65+ years     
Other substances 120,516 (62.2) 107,009 (37.8) Ref. Ref. 
BZDs w/out nBZRAs 2,282 (59.3) 2,156 (40.7) 1.13 (0.94, 1.36) 0.93 (0.76, 1.14) 
nBZRAs w/out BZDs 1,134 (67.9) 748 (32.2) 0.78 (0.61, 0.99) 0.72 (0.55, 0.95) 
BZDs + nBZRAs 91 (34.6) 119 (65.4) 3.11 (1.47, 6.57) 2.02 (0.97, 4.21) 
Note: OR=odds ratio, AOR=adjusted odds ratio, 95% CI=95% confidence interval, BZDs=benzodiazepines (include alprazolam 
clonazepam clorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, temazepam, and triazolam), 
nZBRAs=non-benzodiazepine receptor agonists (include zolpidem, zaleplon, and eszopiclone). 
a “More serious outcome” defined as the emergency room visit resulting in an admittance to any department in hospital (i.e., intensive 
critical care unit, surgery, chemical dependence detox/psychiatry, other inpatient unit), transferred, or died. “Less serious outcome” 
defined as an emergency room visit resulting in a discharge home, release to police/jail, or referred to other treatment. 







Supplemental Table 4.1: Emergency department visits involving benzodiazepines 
(BZDs) and non-benzodiazepine receptor agonists (nBZRAs) and severity of disposition 





















AOR (95% CI) 
Other substances 89,013 (74.0) 38,540 (26.0) Ref. Ref. 
BZDs w/out nBZRAs 7,823 (69.6) 3,942 (30.4) 1.24 (1.09, 1.42) 1.25 (1.07, 1.47) 
nBZRAs w/out BZDs 1,653 (81.7) 685 (18.3) 0.64 (0.49, 0.84) 0.51 (0.39, 0.68) 
BZDs + nBZRAs 507 (52.0) 333 (48.0) 2.62 (1.67, 4.12) 2.62 (1.50, 4.57) 
Note: OR=odds ratio, AOR=adjusted odds ratio, 95% CI=95% confidence interval, BZDs=benzodiazepines (include alprazolam 
clonazepam clorazepate, chlordiazepoxide, diazepam, estazolam, flurazepam, lorazepam, oxazepam, temazepam, and triazolam), 
nZBRAs=non-benzodiazepine receptor agonists (include zolpidem, zaleplon, and eszopiclone). 
a “More serious outcome” defined as the emergency room visit resulting in an admittance to any department in hospital (i.e., intensive 
critical care unit, surgery, chemical dependence detox/psychiatry, other inpatient unit), transferred, or died. “Less serious outcome” 
defined as an emergency room visit resulting in a discharge home, release to police/jail, or referred to other treatment. 





Chapter 5: Conclusion 
 
The goal of this dissertation was to examine trends in prescribing of BZDs and 
nBZRAs between 1993 and 2010, and to assess outcomes from emergency department 
visits associated with their use. The dissertation used data from two large nationally 
representative datasets—the National Ambulatory Medical Care Survey (NAMCS) and 
the Drug Abuse Warning Network (DAWN). Overall, we found that prescribing of both 
BZDs as well as nBZRAs increased over the study period, driven by growth in the 
number of, and volume of prescribing by, physicians in non-psychiatry specialties. We 
also found that visits to emergency department settings due to the use of BZDs or 
nBZRAs were more likely to result in a more serious outcome compared to visits in 
which neither of these medication groups were involved. This chapter provides a 
summary of the dissertation’s findings, and discusses public health implications and how 
results may inform future research. 
 
Summary of findings  
Study 1. The purpose of the first study was to examine trends in prescribing of 
BZDs and nBZRAs from 1993-2010 in ambulatory healthcare settings. We found that 
prescribing of BZDs and nBZRAs increased over the study period. In stratified analyses, 
there were increases in prescribing across most patient and visit characteristics assessed. 
Among patients with sleep disorders, however, we observed a large increase in 
prescribing of nBZRAs coinciding with a decline in prescribing of BZDs. We also found 
a growing trend in the co-prescribing of BZDs and nBZRAs at the same visit. 
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 Study 2. The purpose of the second study was to explore whether the increasing 
trend in prescribing of BZDs as well as nBZRAs was due to an increase in the number of 
physicians who prescribe these medications, or an increase in the number of prescriptions 
per prescribing physician. Unsurprisingly, we found that the increase in prescribing of 
nBZRAs was due to both an increase in the number of physicians who prescribe these 
medications and an increase in the volume of prescribing per physician. We also found 
that the increase in prescribing of BZDs was due to an increase in the number of 
prescribers of these medications, but not number of prescriptions per physician.  In 
stratified analyses, the growth in prescribing of BZDs appeared to be driven by increases 
in prescribing among doctors in primary care and other non-psychiatry specialties.   
 Study 3. The purpose of the third study was to examine outcomes from visits to 
emergency departments attributed to BZD or nBZRA use, and to assess differences 
across age groups. Specifically, the study sought to determine whether visits involving 
BZDs and/or nBZRAs resulted in a more serious (e.g., hospitalization) or less serious 
(e.g., discharge home) outcome compared to visits involving other substances.  We found 
visits involving BZDs without nBZRAs, as well as both BZDs and nBZRAs together, 
were associated with a higher odds of experiencing a more serious outcome compared to 
visits involving other substances.  Notably, visits involving both BZDs and nBZRAs 
together had nearly three times higher odds of experiencing a more serious outcome 
compared to visits involving other substances, even after controlling for a number of 
patient characteristics including age, gender, race, the number of reported substances, and 




Public health implications 
 This dissertation found that despite clinical and policy efforts to discourage 
prescribing of BZDs and nBZRAs in the mid-1990s and early-2000s,13-15,61,62,143 
prescribing of these agents continued to grow up until 2010. Growth in prescribing was 
seen across most groups of patients assessed (except for patients with sleep disorders for 
BZDs), and even among older adults, who may be especially vulnerable to adverse side 
effects. As seen in study 2, growth in prescribing of BZDs and nBZRAs was observed 
among doctors who saw mostly older adults (i.e., >50% of their patients were age 65+).  
It is surprising that even with the growing awareness of the potential adverse health 
outcomes associated with BZD and nBZRA use for older adults, and the published 
clinical guidelines such as the Beers Criteria,15,16 prescribing of both medication classes 
still increased even among physicians who saw mostly older adults.  As the results of 
study 3 suggest, visits to emergency departments involving BZDs and/or nBZRAs were 
at greater risk of more serious outcomes across the age range. 
 Study 2 found that one reason for increases in prescribing, in particular for BZDs, 
was a growth in the number of prescribers in primary care and other non-psychiatry 
specialties.  This finding suggests that growth in prescribing of BZDs and nBZRAs may 
be attributable to an increase in physicians prescribing these agents who have not 
historically prescribed psychiatric medications. Over the past decade, there has been 
growth in prescribing of selective serotonin reuptake inhibitors in primary care 
settings.114 The findings from this dissertation show that this trend may be expanding to 
other psychiatric medication classes including sedative-hypnotics. These findings call for 
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efforts to educate physicians new to prescribing of these agents on identifying patients 
who may experience an adverse health outcome attributable to the use of sedative-
hypnotics.  
 In addition to a growth in prescribing of BZDs and nBZRAs in primary care and 
other non-psychiatric settings, we found a worrisome trend in the co-prescribing of BZDs 
and nBZRAs. The potential for co-prescribing of BZDs and nBZRAs is conceivable—for 
example, a patient may be prescribed a BZD for a chronic anxiety disorder and an 
nBZRA for transient insomnia. However, as BZDs and nBZRAs both act on GABA 
neurotransmitter receptors, there is a heightened risk for severe over-sedation.  Studies 
from clinical trials have shown an additive effect when these medications are co-
administered.135,136 Epidemiological studies have also shown a greater risk of hip-
fractures associated with combining these agents.75 Findings from study 3 show that ED 
visits involving the combined use of BZDs and nBZRAs were associated with an 
increased risk of more serious outcomes compared to visits involving other substances.  
Guidelines need to be developed to discourage the co-prescribing of these agents. 
 While prescribing of sedative-hypnotics has increased over the past two or three 
decades, behavioral therapies for anxiety disorders and insomnia have also been 
developed.98,99 Behavioral and other non-pharmacological therapies for insomnia and 
anxiety disorders are preferable to use of medications because they have been shown to 
be more effective over time,1 and do not have the potential for adverse health outcomes. 
For anxiety disorders, cognitive-behavioral therapy (CBT) draws from principles of 
cognitive and behavioral psychology and provides a systematic approach for addressing 
cognitive-distortions that may cause anxiety.144 Exposure therapy consists of gradually 
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exposing individuals to fearful experiences to encourage them to confront phobias or 
other anxieties.145 For insomnia, a number of behavioral interventions have shown to be 
quite useful. Sleep restriction therapy limits the time in bed for a patient in order to 
promote better sleep quality and decrease sleep fragmentation throughout the night.122 
Stimulus control therapy seeks to limit arousal before bed and to encourage patients to 
associate their bed with sleeping only.123 Sleep hygiene education can also be used to 
encourage healthy bedtime rituals (e.g., not eating or drinking alcohol immediately prior 
to bed time, dimming lights before bed).1 Formal treatment programs such as CBT for 
insomnia (CBT-i)2 draw on these therapies to provide a structured treatment plan that can 
decrease arousal that interferes with sleep and improve sleep quality overall.123 
 With regards to insomnia treatments, despite CBT-i’s demonstrated effectiveness, 
very few clinicians are trained to deliver the treatment.124 For example, the Society of 
Behavioral Sleep Medicine in tandem with the American Board of Sleep Medicine offers 
a credentialing program in behavioral sleep medicine which involves techniques of CBT-
i;146 however, the costs and the required time investment may be a barrier to training for 
many clinicians. Additionally, primary care physicians, who are increasingly prescribing 
sedative-hypnotics, may not have the time to engage their patients in this treatment given 
the need to meet with so many patients.147 While fellowship opportunities for training in 
behavioral sleep medicine do exist, the uptake of this specialty is not particularly high,124 
and more incentives are needed to encourage physicians to go into the field. Efforts to 
improve the dissemination of CBT-i are ongoing139 and one line of research is 
investigating ways to implement CBT-i techniques in primary care settings.148,149 
Additionally, the Veterans Administration is rolling out CBT-i interventions in their 
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hospitals across the United States.150 Despite these innovative efforts, more work is 
needed to disseminate behavioral sleep treatments. 
 
Limitations of studies 
 The analyses that are the basis for this dissertation had a number of limitations.  
First, data for both NAMCS and DAWN were extracted from medical records, and 
consequently our results were open to reporting bias. Busier clinical offices or EDs with a 
more complex patient load may have been less detailed in their recordings than others. 
Furthermore, non-response for busier offices may limit the representativeness of the data. 
Second, data from both NAMCS and DAWN are based on individual visits. For NAMCS, 
this may be an issue as some patients (especially older adults) see multiple providers; 
consequently, it is possible that we did not capture all instances of BZDs or nBZRAs 
prescribed. Our results may thus be a conservative estimate.  Third, eligibility for visits in 
DAWN was dependent on hospital staff recognizing that the ED visit involved a 
substance.  It is possible that visits were not included in DAWN because not enough 
information was provided on medical records or volunteered by the patient. Fourth, we 
did not have information on the indication for medication use.  While NAMCS provided 
data on diagnoses given at the visit, we did not know the specific reason for the 
medication being prescribed.  Similarly, DAWN does not report the indication of the use 
of prescribed medications involved in the visit, only that it was a contributor to the ED 
visit.  Changes in the indications of the prescription of sedative-hypnotics may have 
resulted in the trends we observed in studies 1 and 2. These changes as well as changes in 
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Findings from this dissertation show that despite efforts to discourage prescribing 
of BZDs and nBZRAs, prescribing of these agents has increased over the past two 
decades.  We found that this was in part driven by large increases in prescribing in 
primary care, and among physicians in other non-psychiatry specialties. We also found 
that this increased prescribing may be associated with more serious outcomes in EDs. 
As BZDs and nBZRAs gradually lose their patents, pharmaceutical companies 
have developed newer sleep-aid medications.  For example, Intermezzo, a zolpidem 
derivative, was approved by the Food and Drug Administration in 2011 for middle-of-
the-night awakenings.94 Tasimelteon (brand name: Hetlioz) was recently approved for the 
treatment of irregular circadian rhythm patterns in patients with visual impairments.95 
Suvorexant (brand name: Belsomra), treats insomnia by inhibiting absorption of the 
neurotransmitter orexin, which promotes wakefulness.96 It is not clear how these 
medications will be tolerated when used in the usual care settings and over longer periods 
of time than commonly used in randomized clinical trials. While clinical trials have 
shown these medications to be “safe and effective,” these studies are based on a smaller 
number of patients that tend to be healthier than the typical individuals prescribed these 
medications in usual care settings.  Large pharmaco-epidemiological studies are needed 
to assess the safety of these agents in the general population. 
Little is known about how the introduction of these new pharmacological 
treatments will influence the landscape of prescribing of sleep-aids and other sedative-
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hypnotics in the US. Regardless, further efforts should focus on improving the 
dissemination and acceptability of safer behavioral treatments for sleep disorders. Such 
efforts could minimize the public health burden of sleep problems and adverse health 
outcomes from use of BZDs and nBZRAs, as well as improve the quality of life for the 
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